metformin has been researched along with Local Neoplasm Recurrence in 87 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine whether the administration of adjuvant metformin (vs placebo) to patients with breast cancer without diabetes improves outcomes." | 9.51 | Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical Trial. ( Abramson, VG; Bliss, JM; Chen, BE; Ennis, M; Gelmon, KA; Goodwin, PJ; Hershman, DL; Hobday, TJ; Lemieux, J; Ligibel, JA; Mackey, JR; Mayer, IA; Mukherjee, SD; Oja, C; Parulekar, WR; Rabaglio-Poretti, M; Rastogi, P; Rea, DW; Shepherd, LE; Stambolic, V; Stos, PM; Thompson, AM; Wesolowski, R; Whelan, TJ, 2022) |
| "Metformin use was associated with improved oncological outcomes in patients with non-muscle-invasive bladder cancer treated with intravesical BCG." | 9.51 | Beyond diabetes mellitus: role of metformin in non-muscle-invasive bladder cancer. ( Chiong, E; Kesavan, E; Lata, RM; Mahendran, R; Ong, WYF; Shen, T; Sng, JH; Wang, Z, 2022) |
| "For fertility-sparing management, compared to progestin alone, the outcomes of patients with endometrial hyperplasia and early endometrial cancer were more improved with progestin plus metformin because progestin plus metformin increases the rate of remission and pregnancy." | 9.41 | Progestin plus metformin improves outcomes in patients with endometrial hyperplasia and early endometrial cancer more than progestin alone: a meta-analysis. ( Li, Y; Shao, F; Zhao, Y, 2023) |
| " We assessed the efficacy of metformin in preventing recurrence after medroxyprogesterone acetate (MPA) as fertility-sparing treatment for atypical endometrial hyperplasia (AEH) and EC." | 9.22 | Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer. ( Hanaoka, H; Kiyokawa, T; Koshizaka, M; Mitsuhashi, A; Sato, Y; Shozu, M, 2016) |
| "Previous studies have suggested that metformin might improve survival outcomes in patients with breast cancer." | 9.22 | Efficacy of Metformin in Patients With Breast Cancer Receiving Chemotherapy or Endocrine Therapy: Systematic Review and Meta-analysis. ( Kataoka, Y; Kawaguchi-Sakita, N; Kurata, Y; Morio, K; Shiroshita, A, 2022) |
| " Studies of reproductive-aged women with atypical endometrial hyperplasia or early endometrial cancer who received progestin and metformin or progestin alone for fertility-sparing management, were included in the review." | 9.12 | Outcomes of women treated with progestin and metformin for atypical endometrial hyperplasia and early endometrial cancer: a systematic review and meta-analysis. ( Blake, LE; Chae-Kim, J; Garg, G; Gavrilova-Jordan, L; Hayslip, CC; Kim, TT; Wu, Q, 2021) |
| "The combination of Carboplatin with Paclitaxel is the mainstay treatment for high-grade serous carcinoma; however, many patients with advanced disease undergo relapse due to chemoresistance." | 8.12 | The Antineoplastic Effect of Carboplatin Is Potentiated by Combination with Pitavastatin or Metformin in a Chemoresistant High-Grade Serous Carcinoma Cell Line. ( Duarte, D; Nunes, M; Ricardo, S; Vale, N, 2022) |
| "We studied a large cohort of early-stage, hormone-positive breast cancer patients to determine if there is an association between RS and metformin treatment." | 7.96 | Diabetes and Metformin Association with Recurrence Score in a Large Oncotype Database of Breast Cancer Patients. ( Blanter, J; Cascetta, K; Ru, M; Tharakan, S; Tiersten, A; Zimmerman, B, 2020) |
| "Metformin is associated with satisfactory clinical outcomes among HBV-related HCC patients with diabetes mellitus after radical resection." | 7.96 | Survival advantage associated with metformin usage in hepatocellular carcinoma patients with diabetes mellitus receiving radical resection: a propensity score matching analysis. ( Lin, Y; Luo, CS; Shi, J; Zhou, WP, 2020) |
| "We investigated metformin-induced cytotoxic effects in vitro and assessed the chemopreventive effects of metformin in patients undergoing hepatic resection (HR) for hepatocellular carcinoma (HCC)." | 7.88 | Metformin-associated Chemopreventive Effects on Recurrence After Hepatic Resection of Hepatocellular Carcinoma: From ( Ahn, CS; Ha, TY; Hwang, S; Jung, DH; Jwa, E; Kang, WH; Kim, KH; Kim, N; Lee, KJ; Lee, SG; Lee, YJ; Moon, DB; Park, GC; Song, GW; Tak, E, 2018) |
| "Metformin use in diabetic patients with previous colorectal adenoma is associated with a lower risk of colorectal adenoma recurrence." | 7.85 | The effect of metformin on the recurrence of colorectal adenoma in diabetic patients with previous colorectal adenoma. ( Cheon, JH; Han, MS; Hong, SP; Kim, TI; Kim, WH; Lee, HJ; Park, SJ, 2017) |
| "The purpose of the present study was to determine the potential relationships of glycemic control and use of metformin with non-muscle invasive bladder cancer characteristics." | 7.83 | Impact of Glycemic Control and Metformin Use on the Recurrence and Progression of Non-Muscle Invasive Bladder Cancer in Patients with Diabetes Mellitus. ( Ahn, JH; Hwang, EC; Jung, SI; Kim, SW; Kwon, DD; Yim, SU, 2016) |
| "Sorafenib is recognized as a standard treatment for advanced hepatocellular carcinoma (HCC)." | 7.83 | Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models. ( Cao, M; Cui, Y; Fang, F; Gao, J; Guo, Z; Li, H; Li, Q; Song, T; Sun, H; Yin, H; You, A; Zhang, T; Zhang, W; Zhou, H; Zhu, X; Zuo, B, 2016) |
| "The impact of statins, aspirin and metformin use on recurrence-free (RFS) and overall survival (OS) of patients with biliary tract cancer (BTC) has not been evaluated." | 7.81 | Effects of Statin, Aspirin or Metformin Use on Recurrence-Free and Overall Survival in Patients with Biliary Tract Cancer. ( Aneja, P; Horgan, AM; Knox, JJ; Le, LW; McKeever, E; McNamara, MG, 2015) |
| " Cox regression models addressed the association of diabetes mellitus (DM) and metformin use with disease recurrence, cancer-specific mortality, and any-cause mortality." | 7.80 | Effect of diabetes mellitus and metformin use on oncologic outcomes of patients treated with radical cystectomy for urothelial carcinoma. ( Babjuk, M; Bachmann, A; Chrystal, J; Crivelli, JJ; Faison, T; Fajkovic, H; Karakiewicz, PI; Kluth, L; Lotan, Y; Rieken, M; Scherr, DS; Shariat, SF; Sun, M; Xylinas, E, 2014) |
| "To assess the association between diabetes mellitus (DM) and metformin use with prognosis and outcomes of non-muscle-invasive bladder cancer (NMIBC) PATIENTS AND METHODS: We retrospectively evaluated 1117 patients with NMIBC treated at four institutions between 1996 and 2007." | 7.79 | Association of diabetes mellitus and metformin use with oncological outcomes of patients with non-muscle-invasive bladder cancer. ( Babjuk, M; Bachmann, A; Chrystal, J; Crivelli, JJ; Faison, T; Fajkovic, H; Karakiewicz, PI; Kautzky-Willer, A; Kluth, L; Lotan, Y; Rieken, M; Scherr, DS; Shariat, SF; Xylinas, E, 2013) |
| "Metformin has a potential role in the chemoprevention of colorectal cancer." | 6.82 | Metformin for chemoprevention of metachronous colorectal adenoma or polyps in post-polypectomy patients without diabetes: a multicentre double-blind, placebo-controlled, randomised phase 3 trial. ( Arimoto, J; Hata, Y; Hattori, A; Higurashi, T; Hosono, K; Inayama, Y; Kessoku, T; Komiya, Y; Matsuhashi, N; Nagase, H; Nakajima, A; Sakai, E; Taguri, M; Takahashi, H; Taniguchi, L; Uchiyama, S; Uchiyama, T; Umezawa, S; Yamanaka, S, 2016) |
| "Metformin use was associated with significantly higher objective response rate (ORR) in the overall and PS-matched cohort (79." | 5.72 | Metformin administration is associated with enhanced response to transarterial chemoembolization for hepatocellular carcinoma in type 2 diabetes patients. ( Choi, GH; Choi, WJ; Choi, WS; Jang, ES; Jang, S; Jeong, SH; Jung, WJ; Kim, JW; Lee, JH; Park, J; Yoon, CJ, 2022) |
| "Metformin intake was associated with a favorable outcome in HNM patients, providing possible therapeutic implications for future adjuvant treatment regimes." | 5.72 | Prognostic Relevance of Type 2 Diabetes and Metformin Treatment in Head and Neck Melanoma: Results from a Population-Based Cohort Study. ( Ettl, T; Fischer, R; Gerken, M; Lindner, SR; Ludwig, N; Reichert, TE; Schimnitz, S; Spanier, G; Spoerl, S; Taxis, J, 2022) |
| "To determine whether the administration of adjuvant metformin (vs placebo) to patients with breast cancer without diabetes improves outcomes." | 5.51 | Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical Trial. ( Abramson, VG; Bliss, JM; Chen, BE; Ennis, M; Gelmon, KA; Goodwin, PJ; Hershman, DL; Hobday, TJ; Lemieux, J; Ligibel, JA; Mackey, JR; Mayer, IA; Mukherjee, SD; Oja, C; Parulekar, WR; Rabaglio-Poretti, M; Rastogi, P; Rea, DW; Shepherd, LE; Stambolic, V; Stos, PM; Thompson, AM; Wesolowski, R; Whelan, TJ, 2022) |
| "Metformin use was associated with improved oncological outcomes in patients with non-muscle-invasive bladder cancer treated with intravesical BCG." | 5.51 | Beyond diabetes mellitus: role of metformin in non-muscle-invasive bladder cancer. ( Chiong, E; Kesavan, E; Lata, RM; Mahendran, R; Ong, WYF; Shen, T; Sng, JH; Wang, Z, 2022) |
| "Metformin (MTF) has been reported to target NLK (Nemo-like kinase) to inhibit non-small lung cancer cells." | 5.48 | Metformin Enhances the Effect of Regorafenib and Inhibits Recurrence and Metastasis of Hepatic Carcinoma After Liver Resection via Regulating Expression of Hypoxia Inducible Factors 2α (HIF-2α) and 30 kDa HIV Tat-Interacting Protein (TIP30). ( Guo, X; Yang, L; Yang, Q, 2018) |
| "Colorectal cancer is one of the most common malignancies in the Western world, and even after surgical removal, there is a high recurrence rate." | 5.48 | Association between metformin use after surgery for colorectal cancer and oncological outcomes: A nationwide register-based study. ( Fransgaard, T; Gögenur, I; Thygesen, LC, 2018) |
| "All patients registered as having hepatocellular carcinoma between January 1995 and December 2011 in a nationwide database were retrospectively analysed." | 5.46 | Metformin confers risk reduction for developing hepatocellular carcinoma recurrence after liver resection. ( Chan, KM; Chiou, MJ; Chou, HS; Hsu, JT; Kuo, CF; Lee, CF; Lee, WC; Wang, YC; Wu, TH; Wu, TJ, 2017) |
| "For fertility-sparing management, compared to progestin alone, the outcomes of patients with endometrial hyperplasia and early endometrial cancer were more improved with progestin plus metformin because progestin plus metformin increases the rate of remission and pregnancy." | 5.41 | Progestin plus metformin improves outcomes in patients with endometrial hyperplasia and early endometrial cancer more than progestin alone: a meta-analysis. ( Li, Y; Shao, F; Zhao, Y, 2023) |
| "Previous studies have suggested that metformin might improve survival outcomes in patients with breast cancer." | 5.22 | Efficacy of Metformin in Patients With Breast Cancer Receiving Chemotherapy or Endocrine Therapy: Systematic Review and Meta-analysis. ( Kataoka, Y; Kawaguchi-Sakita, N; Kurata, Y; Morio, K; Shiroshita, A, 2022) |
| " We assessed the efficacy of metformin in preventing recurrence after medroxyprogesterone acetate (MPA) as fertility-sparing treatment for atypical endometrial hyperplasia (AEH) and EC." | 5.22 | Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer. ( Hanaoka, H; Kiyokawa, T; Koshizaka, M; Mitsuhashi, A; Sato, Y; Shozu, M, 2016) |
| " Studies of reproductive-aged women with atypical endometrial hyperplasia or early endometrial cancer who received progestin and metformin or progestin alone for fertility-sparing management, were included in the review." | 5.12 | Outcomes of women treated with progestin and metformin for atypical endometrial hyperplasia and early endometrial cancer: a systematic review and meta-analysis. ( Blake, LE; Chae-Kim, J; Garg, G; Gavrilova-Jordan, L; Hayslip, CC; Kim, TT; Wu, Q, 2021) |
| "The combination of Carboplatin with Paclitaxel is the mainstay treatment for high-grade serous carcinoma; however, many patients with advanced disease undergo relapse due to chemoresistance." | 4.12 | The Antineoplastic Effect of Carboplatin Is Potentiated by Combination with Pitavastatin or Metformin in a Chemoresistant High-Grade Serous Carcinoma Cell Line. ( Duarte, D; Nunes, M; Ricardo, S; Vale, N, 2022) |
| "We studied a large cohort of early-stage, hormone-positive breast cancer patients to determine if there is an association between RS and metformin treatment." | 3.96 | Diabetes and Metformin Association with Recurrence Score in a Large Oncotype Database of Breast Cancer Patients. ( Blanter, J; Cascetta, K; Ru, M; Tharakan, S; Tiersten, A; Zimmerman, B, 2020) |
| "Metformin is associated with satisfactory clinical outcomes among HBV-related HCC patients with diabetes mellitus after radical resection." | 3.96 | Survival advantage associated with metformin usage in hepatocellular carcinoma patients with diabetes mellitus receiving radical resection: a propensity score matching analysis. ( Lin, Y; Luo, CS; Shi, J; Zhou, WP, 2020) |
| "We investigated metformin-induced cytotoxic effects in vitro and assessed the chemopreventive effects of metformin in patients undergoing hepatic resection (HR) for hepatocellular carcinoma (HCC)." | 3.88 | Metformin-associated Chemopreventive Effects on Recurrence After Hepatic Resection of Hepatocellular Carcinoma: From ( Ahn, CS; Ha, TY; Hwang, S; Jung, DH; Jwa, E; Kang, WH; Kim, KH; Kim, N; Lee, KJ; Lee, SG; Lee, YJ; Moon, DB; Park, GC; Song, GW; Tak, E, 2018) |
| "Metformin use in diabetic patients with previous colorectal adenoma is associated with a lower risk of colorectal adenoma recurrence." | 3.85 | The effect of metformin on the recurrence of colorectal adenoma in diabetic patients with previous colorectal adenoma. ( Cheon, JH; Han, MS; Hong, SP; Kim, TI; Kim, WH; Lee, HJ; Park, SJ, 2017) |
| "The purpose of the present study was to determine the potential relationships of glycemic control and use of metformin with non-muscle invasive bladder cancer characteristics." | 3.83 | Impact of Glycemic Control and Metformin Use on the Recurrence and Progression of Non-Muscle Invasive Bladder Cancer in Patients with Diabetes Mellitus. ( Ahn, JH; Hwang, EC; Jung, SI; Kim, SW; Kwon, DD; Yim, SU, 2016) |
| "Sorafenib is recognized as a standard treatment for advanced hepatocellular carcinoma (HCC)." | 3.83 | Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models. ( Cao, M; Cui, Y; Fang, F; Gao, J; Guo, Z; Li, H; Li, Q; Song, T; Sun, H; Yin, H; You, A; Zhang, T; Zhang, W; Zhou, H; Zhu, X; Zuo, B, 2016) |
| "The impact of statins, aspirin and metformin use on recurrence-free (RFS) and overall survival (OS) of patients with biliary tract cancer (BTC) has not been evaluated." | 3.81 | Effects of Statin, Aspirin or Metformin Use on Recurrence-Free and Overall Survival in Patients with Biliary Tract Cancer. ( Aneja, P; Horgan, AM; Knox, JJ; Le, LW; McKeever, E; McNamara, MG, 2015) |
| " Cox regression models addressed the association of diabetes mellitus (DM) and metformin use with disease recurrence, cancer-specific mortality, and any-cause mortality." | 3.80 | Effect of diabetes mellitus and metformin use on oncologic outcomes of patients treated with radical cystectomy for urothelial carcinoma. ( Babjuk, M; Bachmann, A; Chrystal, J; Crivelli, JJ; Faison, T; Fajkovic, H; Karakiewicz, PI; Kluth, L; Lotan, Y; Rieken, M; Scherr, DS; Shariat, SF; Sun, M; Xylinas, E, 2014) |
| "A 74-year-old female patient with a locally recurrent breast cancer developed hyperglycaemia, which started 2 weeks after the initiation of treatment with everolimus 10 mg once daily." | 3.80 | [Hyperglycaemia during treatment with everolimus]. ( Beijnen, JH; Huitema, AD; Opdam, FL; Schellens, JH, 2014) |
| "To assess the association between diabetes mellitus (DM) and metformin use with prognosis and outcomes of non-muscle-invasive bladder cancer (NMIBC) PATIENTS AND METHODS: We retrospectively evaluated 1117 patients with NMIBC treated at four institutions between 1996 and 2007." | 3.79 | Association of diabetes mellitus and metformin use with oncological outcomes of patients with non-muscle-invasive bladder cancer. ( Babjuk, M; Bachmann, A; Chrystal, J; Crivelli, JJ; Faison, T; Fajkovic, H; Karakiewicz, PI; Kautzky-Willer, A; Kluth, L; Lotan, Y; Rieken, M; Scherr, DS; Shariat, SF; Xylinas, E, 2013) |
| "Metformin shows preclinical anti-cancer activity through multiple pathways." | 3.30 | A phase I trial of metformin in combination with vincristine, irinotecan, and temozolomide in children with relapsed or refractory solid and central nervous system tumors: A report from the national pediatric cancer foundation. ( Badgett, T; Crimella, J; Fridley, BL; Gill, J; Gorlick, R; Llosa, N; Metts, JL; Reed, D; Sandler, E; Sansil, S; Smith, T; Thapa, R; Thompson, P; Trucco, M; Weiser, DA, 2023) |
| " The recommended phase II dose is eight weeks of a ModAD combined with 850 mg metformin twice daily." | 3.01 | A Phase I clinical trial of dose-escalated metabolic therapy combined with concomitant radiation therapy in high-grade glioma. ( Amit, U; Anikster, Y; Champ, CE; Cohen, ZR; Furman, O; Genssin, H; Hemi, R; Jan, E; Kanety, H; Lawrence, YR; Mardor, Y; Pechthold, RG; Plotkin, L; Porper, K; Shimoni-Sebag, A; Shpatz, Y; Symon, Z; Talianski, A; Zach, L, 2021) |
| " The recommended dose of metformin combined with nivolumab is determined in part 1." | 2.87 | Study Protocol: Phase-Ib Trial of Nivolumab Combined With Metformin for Refractory/Recurrent Solid Tumors. ( Fujiwara, T; Hotta, K; Kiura, K; Kozuki, T; Kubo, T; Ninomiya, T; Okada, H; Toyooka, S; Udono, H, 2018) |
| "In acute lymphoblastic leukemia (ALL), high ABCB1 gene expression has been associated with treatment resistance, which affects patient prognosis." | 2.87 | Effect of metformin on the survival of patients with ALL who express high levels of the ABCB1 drug resistance gene. ( Cerón-Maldonado, R; Collazo-Jaloma, J; Kassack-Ipiña, JJ; Martínez-Tovar, A; Meléndez-Mier, G; Olarte-Carrillo, I; Ramos-Peñafiel, C; Rozen-Fuller, E, 2018) |
| "Metformin has a potential role in the chemoprevention of colorectal cancer." | 2.82 | Metformin for chemoprevention of metachronous colorectal adenoma or polyps in post-polypectomy patients without diabetes: a multicentre double-blind, placebo-controlled, randomised phase 3 trial. ( Arimoto, J; Hata, Y; Hattori, A; Higurashi, T; Hosono, K; Inayama, Y; Kessoku, T; Komiya, Y; Matsuhashi, N; Nagase, H; Nakajima, A; Sakai, E; Taguri, M; Takahashi, H; Taniguchi, L; Uchiyama, S; Uchiyama, T; Umezawa, S; Yamanaka, S, 2016) |
| "An otherwise untreated rectal cancer, progressing over 3 years, regressed after severe toxic dermatitis lasting over one week." | 2.72 | Immunology of tissue homeostasis, ovarian cancer growth and regression, and long lasting cancer immune prophylaxis - review of literature. ( Bukovsky, A, 2021) |
| "The main challenge in ovarian cancer treatment is the management of recurrences." | 2.66 | Recycling the Purpose of Old Drugs to Treat Ovarian Cancer. ( Bartosch, C; Henriques Abreu, M; Nunes, M; Ricardo, S, 2020) |
| " Qualitative synthesis also suggests an apparently dose-response relationship and increased benefit when administered alone." | 2.58 | Protective effects of metformin, statins and anti-inflammatory drugs on head and neck cancer: A systematic review. ( Estrugo Devesa, A; Jané-Salas, E; López-López, J; Saka Herrán, C, 2018) |
| "Metformin use was associated with a significantly higher overall and disease-free survival, in a subset of diabetic patients." | 2.55 | Potentiating the effects of radiotherapy in rectal cancer: the role of aspirin, statins and metformin as adjuncts to therapy. ( Chambers, AC; Cotton, DE; Gash, KJ; Thomas, MG; Williams, AC, 2017) |
| "Breast cancer is the most common cancer in women worldwide." | 2.52 | Update on breast cancer risk prediction and prevention. ( Cuzick, J; Sestak, I, 2015) |
| "Metformin has been demonstrated to induce apoptosis in cancer cells." | 1.91 | Metformin sensitizes AML cells to venetoclax through endoplasmic reticulum stress-CHOP pathway. ( Chen, J; Du, J; Hua, L; Huang, K; Jiang, X; Lai, J; Li, Y; Liu, F; Yang, N; Yu, Z; Zeng, H, 2023) |
| "Metformin is an antidiabetic drug; recent reports have indicated its anti-cancer effects in various cancers, and it is known to have synergistic effects with other drugs." | 1.72 | Synergic Effect of Metformin and Everolimus on Mitochondrial Dynamics of Renal Cell Carcinoma. ( Han, WK; Hong, SH; Hwang, HJ; Lee, KS; Park, SY; Yoon, YE, 2022) |
| "Metformin use was associated with significantly higher objective response rate (ORR) in the overall and PS-matched cohort (79." | 1.72 | Metformin administration is associated with enhanced response to transarterial chemoembolization for hepatocellular carcinoma in type 2 diabetes patients. ( Choi, GH; Choi, WJ; Choi, WS; Jang, ES; Jang, S; Jeong, SH; Jung, WJ; Kim, JW; Lee, JH; Park, J; Yoon, CJ, 2022) |
| "Metformin intake was associated with a favorable outcome in HNM patients, providing possible therapeutic implications for future adjuvant treatment regimes." | 1.72 | Prognostic Relevance of Type 2 Diabetes and Metformin Treatment in Head and Neck Melanoma: Results from a Population-Based Cohort Study. ( Ettl, T; Fischer, R; Gerken, M; Lindner, SR; Ludwig, N; Reichert, TE; Schimnitz, S; Spanier, G; Spoerl, S; Taxis, J, 2022) |
| "To investigate the impact of type 2 diabetes mellitus (T2DM) and metformin treatment on the prognosis of oral squamous cell carcinoma (OSCC) patients received radical surgical treatment." | 1.56 | Metformin reduces the increased risk of oral squamous cell carcinoma recurrence in patients with type 2 diabetes mellitus: A cohort study with propensity score analyses. ( Chen, W; Hu, X; Huang, D; Huang, L; Mao, T; Shu, Y; Su, T; Wang, C; Wang, Z; Xia, K; Xiong, H; Yang, L; Yu, J, 2020) |
| "Metformin treatment did not influence any of the outcomes." | 1.51 | Association between diabetes and oncological outcomes in patients undergoing neoadjuvant chemo-radiotherapy for rectal cancer. ( Fransgaard, T; Gögenur, I; Hallas, J; Thygesen, LC, 2019) |
| "Metformin treatment relieves the clinical symptoms, reduces the inflammatory reaction indexes and regulates the Treg/Th17 axis in patients with BD, suggesting the potential of metformin as a candidate medicine for treatment of BD." | 1.51 | [Efficacy and safety of metformin for Behcet's disease and its effect on Treg/Th17 balance: a single-blinded, before-after study]. ( Chenhong, L; Dan, L; Jianfei, C; Jianlong, G; Yan, S; Yong, C, 2019) |
| "Recurrence and chemoresistance in colorectal cancer remain important issues for patients treated with conventional therapeutics." | 1.51 | Effects of metformin and phenformin on apoptosis and epithelial-mesenchymal transition in chemoresistant rectal cancer. ( Jang, H; Kim, A; Kim, H; Kim, MJ; Kim, YH; Lee, SB; Lee, SJ; Myung, JK; Park, EH; Park, JH; Park, S; Shim, S, 2019) |
| "Colorectal cancer is one of the most common malignancies in the Western world, and even after surgical removal, there is a high recurrence rate." | 1.48 | Association between metformin use after surgery for colorectal cancer and oncological outcomes: A nationwide register-based study. ( Fransgaard, T; Gögenur, I; Thygesen, LC, 2018) |
| "Metformin (MTF) has been reported to target NLK (Nemo-like kinase) to inhibit non-small lung cancer cells." | 1.48 | Metformin Enhances the Effect of Regorafenib and Inhibits Recurrence and Metastasis of Hepatic Carcinoma After Liver Resection via Regulating Expression of Hypoxia Inducible Factors 2α (HIF-2α) and 30 kDa HIV Tat-Interacting Protein (TIP30). ( Guo, X; Yang, L; Yang, Q, 2018) |
| "Recurrences, metastases, secondary cancers, survival and carcinoembryonic antigen levels were compared using t test and chi-squared test." | 1.46 | Metformin Has Positive Therapeutic Effects in Colon Cancer and Lung Cancer. ( Frieson, D; Henderson, D; Solomon, SS; Zuber, J, 2017) |
| "All patients registered as having hepatocellular carcinoma between January 1995 and December 2011 in a nationwide database were retrospectively analysed." | 1.46 | Metformin confers risk reduction for developing hepatocellular carcinoma recurrence after liver resection. ( Chan, KM; Chiou, MJ; Chou, HS; Hsu, JT; Kuo, CF; Lee, CF; Lee, WC; Wang, YC; Wu, TH; Wu, TJ, 2017) |
| "Patients included 1 with a history of oral cavity squamous cell carcinoma (SCC) and 2 with a history of laryngeal SCC." | 1.46 | Metformin Prevents the Progression of Dysplastic Mucosa of the Head and Neck to Carcinoma in Nondiabetic Patients. ( Blitzer, A; Lerner, MZ; Mor, N; Paek, H; Strome, M, 2017) |
| "Metformin has recently been discussed to possess anticancer activities and to positively affect the risk of developing cancer." | 1.43 | The prognostic role of metformin in patients with endometrial cancer: a retrospective study. ( Bergmeister, B; Grimm, C; Koelbl, H; Polterauer, S; Reinthaller, A; Seebacher, V, 2016) |
| "However, for those patients with type I endometrial cancer, only 1 patient (1." | 1.43 | Use of Metformin in Obese Women With Type I Endometrial Cancer Is Associated With a Reduced Incidence of Cancer Recurrence. ( Burnett, AF; Gehlot, A; Hall, C; Stone, RL; Zorn, KK, 2016) |
| "Metformin use did not increase or decrease the likelihood of chemotherapy-related grade 3 or higher adverse events." | 1.43 | Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer Treatment Group N0147 (Alliance). ( Alberts, SR; Chan, E; Foster, NR; Gill, S; Goldberg, RM; Grothey, A; Kahlenberg, MS; Nair, SG; Sargent, DJ; Shi, Q; Shields, AF; Singh, PP; Sinicrope, FA, 2016) |
| "Animal and in-vitro prostate cancer (PCa) models have demonstrated decreased tumor growth with metformin, however the precise mechanisms are unknown." | 1.42 | Metformin effects on biochemical recurrence and metabolic signaling in the prostate. ( Gore, JL; Holt, S; Hu, E; Lin, DW; Morrissey, C; Plymate, S; Porter, MP; Winters, B; Wooldridge, B; Wright, JL; Zeliadt, SB; Zhang, X, 2015) |
| "The metformin was used in 120 (46." | 1.42 | Metformin use improves the survival of diabetic combined small-cell lung cancer patients. ( Chen, L; Gao, F; Jia, Y; Kong, F; Li, X; Liu, G; Liu, H; Yu, J; Zheng, R, 2015) |
| "Given the growing breast cancer survivor population, further research in larger, more diverse populations is warranted." | 1.42 | Associations between diabetes medication use and risk of second breast cancer events and mortality. ( Boudreau, DM; Calip, GS; Hoskins, KF; Yu, O, 2015) |
| "Metformin has emerged as a potential anticancer agent." | 1.42 | Metformin represses cancer cells via alternate pathways in N-cadherin expressing vs. N-cadherin deficient cells. ( Cai, C; Ge, R; Olumi, AF; Otsetov, AG; Wang, Z; Wu, CL; Wu, S; Zhong, W; Zhuo, Y, 2015) |
| "Metformin use was not associated with a risk reduction in BCR, SP, or ACM." | 1.40 | Effect of metformin on prostate cancer outcomes after radical prostatectomy. ( Bergstralh, EJ; Carlson, RE; Eisenberg, MS; Karnes, RJ; Kaushik, D; Rangel, LJ, 2014) |
| "Locally advanced rectal cancer is commonly treated with chemoradiation prior to total mesorectal excision (TME)." | 1.39 | Metformin use and improved response to therapy in rectal cancer. ( Chang, GJ; Crane, CH; Das, P; Delclos, ME; Eng, C; Garrett, CR; Kelly, P; Krishnan, S; Rodriguez-Bigas, MA; Sandulache, VC; Skibber, JM; Skinner, HD, 2013) |
| "Metformin use was associated with more recent year of surgery (P<0." | 1.39 | Metformin does not affect risk of biochemical recurrence following radical prostatectomy: results from the SEARCH database. ( Abern, MR; Allott, EH; Amling, CL; Aronson, WJ; Cooperberg, MR; Freedland, SJ; Gerber, L; Kane, CJ; Keto, CJ; Moorman, PG; Terris, MK, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 54 (62.07) | 24.3611 |
| 2020's | 33 (37.93) | 2.80 |
| Authors | Studies |
|---|---|
| Chae-Kim, J | 1 |
| Garg, G | 1 |
| Gavrilova-Jordan, L | 1 |
| Blake, LE | 1 |
| Kim, TT | 1 |
| Wu, Q | 2 |
| Hayslip, CC | 1 |
| Remenár, É | 1 |
| Dóczi, R | 1 |
| Dirner, A | 1 |
| Sipos, A | 1 |
| Perjési, A | 1 |
| Tihanyi, D | 1 |
| Vodicska, B | 1 |
| Lakatos, D | 1 |
| Horváth, K | 1 |
| Kajáry, K | 1 |
| Schwáb, R | 1 |
| Déri, J | 1 |
| Lengyel, CG | 1 |
| Várkondi, E | 1 |
| Vályi-Nagy, I | 1 |
| Peták, I | 1 |
| Baeri, A | 1 |
| Levraut, M | 1 |
| Diazzi, S | 1 |
| Camuzard, O | 1 |
| Cegarra-Escolano, M | 1 |
| Ploumellec, MA | 1 |
| Balaguer, T | 1 |
| Fassy, J | 1 |
| Rezzonico, R | 1 |
| Bellusci, S | 1 |
| Mari, B | 1 |
| Vassaux, G | 1 |
| Goodwin, PJ | 1 |
| Chen, BE | 1 |
| Gelmon, KA | 1 |
| Whelan, TJ | 1 |
| Ennis, M | 1 |
| Lemieux, J | 1 |
| Ligibel, JA | 2 |
| Hershman, DL | 1 |
| Mayer, IA | 1 |
| Hobday, TJ | 1 |
| Bliss, JM | 1 |
| Rastogi, P | 1 |
| Rabaglio-Poretti, M | 1 |
| Mukherjee, SD | 1 |
| Mackey, JR | 1 |
| Abramson, VG | 1 |
| Oja, C | 1 |
| Wesolowski, R | 1 |
| Thompson, AM | 1 |
| Rea, DW | 1 |
| Stos, PM | 1 |
| Shepherd, LE | 1 |
| Stambolic, V | 1 |
| Parulekar, WR | 1 |
| Hong, SH | 1 |
| Lee, KS | 1 |
| Hwang, HJ | 1 |
| Park, SY | 1 |
| Han, WK | 1 |
| Yoon, YE | 1 |
| Jung, WJ | 1 |
| Jang, S | 1 |
| Choi, WJ | 1 |
| Park, J | 1 |
| Choi, GH | 1 |
| Jang, ES | 1 |
| Jeong, SH | 2 |
| Choi, WS | 1 |
| Lee, JH | 1 |
| Yoon, CJ | 1 |
| Kim, JW | 1 |
| Metts, JL | 1 |
| Trucco, M | 1 |
| Weiser, DA | 1 |
| Thompson, P | 1 |
| Sandler, E | 1 |
| Smith, T | 1 |
| Crimella, J | 1 |
| Sansil, S | 1 |
| Thapa, R | 1 |
| Fridley, BL | 1 |
| Llosa, N | 1 |
| Badgett, T | 1 |
| Gorlick, R | 1 |
| Reed, D | 1 |
| Gill, J | 1 |
| Waissengrin, B | 3 |
| Zahavi, T | 3 |
| Salmon-Divon, M | 3 |
| Goldberg, A | 3 |
| Wolf, I | 3 |
| Rubinek, T | 3 |
| Winkler, T | 3 |
| Farkash, O | 3 |
| Grinshpun, A | 3 |
| Zubkov, A | 3 |
| Khatib, M | 3 |
| Shachar, SS | 3 |
| Keren, N | 3 |
| Carmi-Levy, I | 3 |
| Ben-David, U | 3 |
| Sonnenblick, A | 3 |
| Spoerl, S | 2 |
| Gerken, M | 1 |
| Schimnitz, S | 1 |
| Taxis, J | 1 |
| Fischer, R | 1 |
| Lindner, SR | 1 |
| Ettl, T | 1 |
| Ludwig, N | 1 |
| Reichert, TE | 1 |
| Spanier, G | 1 |
| Nunes, M | 2 |
| Duarte, D | 1 |
| Vale, N | 1 |
| Ricardo, S | 2 |
| Ushijima, K | 1 |
| Tsuda, N | 1 |
| Yamagami, W | 1 |
| Mitsuhashi, A | 2 |
| Mikami, M | 1 |
| Yaegashi, N | 1 |
| Enomoto, T | 1 |
| Georgopoulos, NS | 1 |
| Tolia, M | 1 |
| Mauri, D | 1 |
| Kamposioras, K | 1 |
| Charalampakis, N | 1 |
| Tsoukalas, N | 1 |
| Gkantaifi, A | 1 |
| Khan, S | 1 |
| Chang, SH | 1 |
| Seyerle, AA | 1 |
| Wang, M | 1 |
| Hicks, V | 1 |
| Drake, BF | 1 |
| Hua, L | 1 |
| Yang, N | 1 |
| Li, Y | 7 |
| Huang, K | 1 |
| Jiang, X | 3 |
| Liu, F | 1 |
| Yu, Z | 1 |
| Chen, J | 2 |
| Lai, J | 1 |
| Du, J | 1 |
| Zeng, H | 1 |
| Shao, F | 1 |
| Zhao, Y | 3 |
| Pencik, J | 1 |
| Philippe, C | 1 |
| Schlederer, M | 1 |
| Atas, E | 1 |
| Pecoraro, M | 1 |
| Grund-Gröschke, S | 1 |
| Li, WJ | 1 |
| Tracz, A | 1 |
| Heidegger, I | 1 |
| Lagger, S | 1 |
| Trachtová, K | 1 |
| Oberhuber, M | 1 |
| Heitzer, E | 1 |
| Aksoy, O | 1 |
| Neubauer, HA | 1 |
| Wingelhofer, B | 1 |
| Orlova, A | 1 |
| Witzeneder, N | 1 |
| Dillinger, T | 1 |
| Redl, E | 1 |
| Greiner, G | 1 |
| D'Andrea, D | 1 |
| Östman, JR | 1 |
| Tangermann, S | 1 |
| Hermanova, I | 1 |
| Schäfer, G | 1 |
| Sternberg, F | 1 |
| Pohl, EE | 1 |
| Sternberg, C | 1 |
| Varady, A | 1 |
| Horvath, J | 1 |
| Stoiber, D | 1 |
| Malcolm, TI | 1 |
| Turner, SD | 1 |
| Parkes, EE | 1 |
| Hantusch, B | 1 |
| Egger, G | 1 |
| Rose-John, S | 1 |
| Poli, V | 1 |
| Jain, S | 1 |
| Armstrong, CWD | 1 |
| Hoermann, G | 1 |
| Goffin, V | 1 |
| Aberger, F | 1 |
| Moriggl, R | 1 |
| Carracedo, A | 1 |
| McKinney, C | 1 |
| Kennedy, RD | 1 |
| Klocker, H | 1 |
| Speicher, MR | 1 |
| Tang, DG | 1 |
| Moazzami, AA | 1 |
| Heery, DM | 1 |
| Hacker, M | 1 |
| Kenner, L | 1 |
| Luo, CS | 1 |
| Lin, Y | 1 |
| Zhou, WP | 1 |
| Shi, J | 1 |
| de Mestier, L | 1 |
| Védie, AL | 1 |
| Faron, M | 1 |
| Cros, J | 1 |
| Rebours, V | 1 |
| Hentic, O | 1 |
| Do Cao, C | 1 |
| Bardet, P | 1 |
| Lévy, P | 1 |
| Sauvanet, A | 1 |
| Ruszniewski, P | 1 |
| Hammel, P | 1 |
| Acosta-Torres, S | 1 |
| Murdock, T | 1 |
| Matsuno, R | 1 |
| Beavis, AL | 1 |
| Stone, RL | 2 |
| Wethington, SL | 1 |
| Levinson, K | 1 |
| Grumbine, F | 1 |
| Ferriss, JS | 1 |
| Tanner, EJ | 1 |
| Fader, AN | 1 |
| Ravishankar, A | 1 |
| Zhang, T | 5 |
| Lindgren, BR | 1 |
| Farah, RS | 1 |
| Dong, Z | 2 |
| Goldfarb, NI | 1 |
| Tharakan, S | 1 |
| Zimmerman, B | 1 |
| Ru, M | 1 |
| Blanter, J | 1 |
| Cascetta, K | 1 |
| Tiersten, A | 1 |
| Wang, Z | 4 |
| Ong, WYF | 1 |
| Shen, T | 1 |
| Sng, JH | 1 |
| Lata, RM | 1 |
| Mahendran, R | 1 |
| Kesavan, E | 1 |
| Chiong, E | 1 |
| Nguépy Keubo, FR | 1 |
| Mboua, PC | 1 |
| Djifack Tadongfack, T | 1 |
| Fokouong Tchoffo, E | 1 |
| Tasson Tatang, C | 1 |
| Ide Zeuna, J | 1 |
| Noupoue, EM | 1 |
| Tsoplifack, CB | 1 |
| Folefack, GO | 1 |
| Kettani, M | 1 |
| Bandelier, P | 1 |
| Huo, J | 1 |
| Li, H | 5 |
| Yu, D | 1 |
| Arulsamy, N | 1 |
| AlAbbad, S | 1 |
| Sardot, T | 1 |
| Lekashvili, O | 1 |
| Decato, D | 1 |
| Lelj, F | 1 |
| Alexander Ross, JB | 1 |
| Rosenberg, E | 1 |
| Nazir, H | 1 |
| Muthuswamy, N | 1 |
| Louis, C | 1 |
| Jose, S | 1 |
| Prakash, J | 1 |
| Buan, MEM | 1 |
| Flox, C | 1 |
| Chavan, S | 1 |
| Shi, X | 1 |
| Kauranen, P | 1 |
| Kallio, T | 1 |
| Maia, G | 1 |
| Tammeveski, K | 1 |
| Lymperopoulos, N | 1 |
| Carcadea, E | 1 |
| Veziroglu, E | 1 |
| Iranzo, A | 1 |
| M Kannan, A | 1 |
| Arunamata, A | 1 |
| Tacy, TA | 1 |
| Kache, S | 1 |
| Mainwaring, RD | 1 |
| Ma, M | 1 |
| Maeda, K | 1 |
| Punn, R | 1 |
| Noguchi, S | 1 |
| Hahn, S | 3 |
| Iwasa, Y | 3 |
| Ling, J | 2 |
| Voccio, JP | 2 |
| Kim, Y | 4 |
| Song, J | 4 |
| Bascuñán, J | 2 |
| Chu, Y | 1 |
| Tomita, M | 1 |
| Cazorla, M | 1 |
| Herrera, E | 1 |
| Palomeque, E | 1 |
| Saud, N | 1 |
| Hoplock, LB | 1 |
| Lobchuk, MM | 1 |
| Lemoine, J | 1 |
| Li, X | 11 |
| Henson, MA | 1 |
| Unsihuay, D | 1 |
| Qiu, J | 2 |
| Swaroop, S | 1 |
| Nagornov, KO | 1 |
| Kozhinov, AN | 1 |
| Tsybin, YO | 1 |
| Kuang, S | 1 |
| Laskin, J | 1 |
| Zin, NNINM | 1 |
| Mohamad, MN | 1 |
| Roslan, K | 1 |
| Abdul Wafi, S | 1 |
| Abdul Moin, NI | 1 |
| Alias, A | 1 |
| Zakaria, Y | 1 |
| Abu-Bakar, N | 1 |
| Naveed, A | 1 |
| Jilani, K | 1 |
| Siddique, AB | 1 |
| Akbar, M | 1 |
| Riaz, M | 1 |
| Mushtaq, Z | 1 |
| Sikandar, M | 1 |
| Ilyas, S | 1 |
| Bibi, I | 1 |
| Asghar, A | 1 |
| Rasool, G | 1 |
| Irfan, M | 1 |
| Li, XY | 1 |
| Zhao, S | 1 |
| Fan, XH | 1 |
| Chen, KP | 1 |
| Hua, W | 1 |
| Liu, ZM | 1 |
| Xue, XD | 1 |
| Zhou, B | 1 |
| Zhang, S | 2 |
| Xing, YL | 1 |
| Chen, MA | 1 |
| Sun, Y | 1 |
| Neradilek, MB | 1 |
| Wu, XT | 1 |
| Zhang, D | 2 |
| Huang, W | 1 |
| Cui, Y | 2 |
| Yang, QQ | 1 |
| Li, HW | 1 |
| Zhao, XQ | 1 |
| Hossein Rashidi, B | 1 |
| Tarafdari, A | 1 |
| Ghazimirsaeed, ST | 1 |
| Shahrokh Tehraninezhad, E | 1 |
| Keikha, F | 1 |
| Eslami, B | 1 |
| Ghazimirsaeed, SM | 1 |
| Jafarabadi, M | 1 |
| Silvani, Y | 1 |
| Lovita, AND | 1 |
| Maharani, A | 1 |
| Wiyasa, IWA | 1 |
| Sujuti, H | 1 |
| Ratnawati, R | 1 |
| Raras, TYM | 1 |
| Lemin, AS | 1 |
| Rahman, MM | 1 |
| Pangarah, CA | 1 |
| Kiyu, A | 1 |
| Zeng, C | 2 |
| Du, H | 1 |
| Lin, D | 1 |
| Jalan, D | 1 |
| Rubagumya, F | 1 |
| Hopman, WM | 1 |
| Vanderpuye, V | 1 |
| Lopes, G | 1 |
| Seruga, B | 1 |
| Booth, CM | 1 |
| Berry, S | 1 |
| Hammad, N | 1 |
| Sajo, EA | 1 |
| Okunade, KS | 1 |
| Olorunfemi, G | 1 |
| Rabiu, KA | 1 |
| Anorlu, RI | 1 |
| Xu, C | 2 |
| Xiang, Y | 1 |
| Xu, X | 1 |
| Zhou, L | 2 |
| Dong, X | 1 |
| Tang, S | 1 |
| Gao, XC | 1 |
| Wei, CH | 1 |
| Zhang, RG | 1 |
| Cai, Q | 1 |
| He, Y | 2 |
| Tong, F | 1 |
| Dong, JH | 1 |
| Wu, G | 1 |
| Dong, XR | 1 |
| Tang, X | 2 |
| Tao, F | 1 |
| Xiang, W | 1 |
| Jin, L | 1 |
| Tao, H | 1 |
| Lei, Y | 1 |
| Gan, H | 1 |
| Huang, Y | 1 |
| Chen, Y | 4 |
| Chen, L | 4 |
| Shan, A | 1 |
| Zhao, H | 2 |
| Wu, M | 2 |
| Ma, Q | 1 |
| Wang, J | 5 |
| Zhang, E | 1 |
| Zhang, J | 3 |
| Xue, F | 1 |
| Deng, L | 1 |
| Liu, L | 2 |
| Yan, Z | 2 |
| Wang, Y | 3 |
| Meng, J | 1 |
| Chen, G | 2 |
| Anastassiadou, M | 1 |
| Bernasconi, G | 1 |
| Brancato, A | 1 |
| Carrasco Cabrera, L | 1 |
| Greco, L | 1 |
| Jarrah, S | 1 |
| Kazocina, A | 1 |
| Leuschner, R | 1 |
| Magrans, JO | 1 |
| Miron, I | 1 |
| Nave, S | 1 |
| Pedersen, R | 1 |
| Reich, H | 1 |
| Rojas, A | 1 |
| Sacchi, A | 1 |
| Santos, M | 1 |
| Theobald, A | 1 |
| Vagenende, B | 1 |
| Verani, A | 1 |
| Du, L | 1 |
| Liu, X | 1 |
| Ren, Y | 1 |
| Li, J | 9 |
| Li, P | 1 |
| Jiao, Q | 1 |
| Meng, P | 1 |
| Wang, F | 2 |
| Wang, YS | 1 |
| Wang, C | 6 |
| Zhou, X | 2 |
| Wang, W | 1 |
| Wang, S | 2 |
| Hou, J | 1 |
| Zhang, A | 1 |
| Lv, B | 1 |
| Gao, C | 1 |
| Pang, D | 1 |
| Lu, K | 1 |
| Ahmad, NH | 1 |
| Wang, L | 1 |
| Zhu, J | 2 |
| Zhang, L | 3 |
| Zhuang, T | 1 |
| Tu, J | 1 |
| Zhao, Z | 1 |
| Qu, Y | 1 |
| Yao, H | 1 |
| Wang, X | 5 |
| Lee, DF | 1 |
| Shen, J | 3 |
| Wen, L | 1 |
| Huang, G | 2 |
| Xie, X | 1 |
| Zhao, Q | 1 |
| Hu, W | 1 |
| Zhang, Y | 4 |
| Wu, X | 1 |
| Lu, J | 2 |
| Li, M | 1 |
| Li, W | 2 |
| Wu, W | 1 |
| Du, F | 1 |
| Ji, H | 1 |
| Yang, X | 2 |
| Xu, Z | 1 |
| Wan, L | 1 |
| Wen, Q | 1 |
| Cho, CH | 1 |
| Zou, C | 1 |
| Xiao, Z | 1 |
| Liao, J | 1 |
| Su, X | 1 |
| Bi, Z | 1 |
| Su, Q | 1 |
| Huang, H | 1 |
| Wei, Y | 2 |
| Gao, Y | 2 |
| Na, KJ | 1 |
| Choi, H | 1 |
| Oh, HR | 1 |
| Kim, YH | 2 |
| Lee, SB | 2 |
| Jung, YJ | 1 |
| Koh, J | 1 |
| Park, S | 2 |
| Lee, HJ | 2 |
| Jeon, YK | 1 |
| Chung, DH | 1 |
| Paeng, JC | 1 |
| Park, IK | 1 |
| Kang, CH | 1 |
| Cheon, GJ | 1 |
| Kang, KW | 1 |
| Lee, DS | 1 |
| Kim, YT | 1 |
| Pajuelo-Lozano, N | 1 |
| Alcalá, S | 1 |
| Sainz, B | 1 |
| Perona, R | 1 |
| Sanchez-Perez, I | 1 |
| Logotheti, S | 1 |
| Marquardt, S | 1 |
| Gupta, SK | 1 |
| Richter, C | 1 |
| Edelhäuser, BAH | 1 |
| Engelmann, D | 1 |
| Brenmoehl, J | 1 |
| Söhnchen, C | 1 |
| Murr, N | 1 |
| Alpers, M | 1 |
| Singh, KP | 1 |
| Wolkenhauer, O | 1 |
| Heckl, D | 1 |
| Spitschak, A | 1 |
| Pützer, BM | 1 |
| Liao, Y | 1 |
| Cheng, J | 1 |
| Kong, X | 1 |
| Li, S | 1 |
| Zhang, M | 4 |
| Zhang, H | 1 |
| Yang, T | 2 |
| Dong, Y | 1 |
| Xu, Y | 1 |
| Yuan, Z | 1 |
| Cao, J | 1 |
| Zheng, Y | 1 |
| Luo, Z | 1 |
| Mei, Z | 1 |
| Yao, Y | 1 |
| Liu, Z | 2 |
| Liang, C | 1 |
| Yang, H | 1 |
| Song, Y | 1 |
| Yu, K | 1 |
| Zhu, C | 1 |
| Huang, Z | 1 |
| Qian, J | 1 |
| Ge, J | 1 |
| Hu, J | 2 |
| Wang, H | 2 |
| Liu, Y | 4 |
| Mi, Y | 1 |
| Kong, H | 1 |
| Xi, D | 1 |
| Yan, W | 1 |
| Luo, X | 1 |
| Ning, Q | 1 |
| Chang, X | 2 |
| Wang, Q | 2 |
| Rathore, MG | 1 |
| Reddy, K | 1 |
| Chen, H | 1 |
| Shin, SH | 1 |
| Ma, WY | 1 |
| Bode, AM | 1 |
| Mu, W | 1 |
| Liu, C | 3 |
| Gao, F | 2 |
| Qi, Y | 1 |
| Lu, H | 1 |
| Zhang, X | 5 |
| Cai, X | 1 |
| Ji, RY | 1 |
| Hou, Y | 3 |
| Tian, J | 2 |
| Shi, Y | 1 |
| Ying, S | 1 |
| Tan, M | 1 |
| Feng, G | 1 |
| Kuang, Y | 1 |
| Chen, D | 1 |
| Wu, D | 3 |
| Zhu, ZQ | 1 |
| Tang, HX | 1 |
| Shi, ZE | 1 |
| Kang, J | 1 |
| Liu, Q | 1 |
| Qi, J | 2 |
| Mu, J | 1 |
| Cong, Z | 1 |
| Chen, S | 2 |
| Fu, D | 1 |
| Li, Z | 2 |
| Celestrin, CP | 1 |
| Rocha, GZ | 1 |
| Stein, AM | 1 |
| Guadagnini, D | 1 |
| Tadelle, RM | 1 |
| Saad, MJA | 1 |
| Oliveira, AG | 1 |
| Bianconi, V | 1 |
| Bronzo, P | 1 |
| Banach, M | 1 |
| Sahebkar, A | 1 |
| Mannarino, MR | 1 |
| Pirro, M | 1 |
| Patsourakos, NG | 1 |
| Kouvari, M | 1 |
| Kotidis, A | 1 |
| Kalantzi, KI | 1 |
| Tsoumani, ME | 1 |
| Anastasiadis, F | 1 |
| Andronikos, P | 1 |
| Aslanidou, T | 1 |
| Efraimidis, P | 1 |
| Georgiopoulos, A | 1 |
| Gerakiou, K | 1 |
| Grigoriadou-Skouta, E | 1 |
| Grigoropoulos, P | 1 |
| Hatzopoulos, D | 1 |
| Kartalis, A | 1 |
| Lyras, A | 1 |
| Markatos, G | 1 |
| Mikrogeorgiou, A | 1 |
| Myroforou, I | 1 |
| Orkopoulos, A | 1 |
| Pavlidis, P | 1 |
| Petras, C | 1 |
| Riga, M | 1 |
| Skouloudi, M | 1 |
| Smyrnioudis, N | 1 |
| Thomaidis, K | 1 |
| Tsikouri, GE | 1 |
| Tsikouris, EI | 1 |
| Zisimos, K | 1 |
| Vavoulis, P | 1 |
| Vitali, MG | 1 |
| Vitsas, G | 1 |
| Vogiatzidis, C | 1 |
| Chantanis, S | 1 |
| Fousas, S | 1 |
| Panagiotakos, DB | 1 |
| Tselepis, AD | 1 |
| Jungen, C | 1 |
| Alken, FA | 1 |
| Eickholt, C | 1 |
| Scherschel, K | 1 |
| Kuklik, P | 1 |
| Klatt, N | 1 |
| Schwarzl, J | 1 |
| Moser, J | 1 |
| Jularic, M | 1 |
| Akbulak, RO | 1 |
| Schaeffer, B | 1 |
| Willems, S | 1 |
| Meyer, C | 1 |
| Nowak, JK | 1 |
| Szczepanik, M | 1 |
| Trypuć, M | 1 |
| Pogorzelski, A | 1 |
| Bobkowski, W | 1 |
| Grytczuk, M | 1 |
| Minarowska, A | 1 |
| Wójciak, R | 1 |
| Walkowiak, J | 1 |
| Lu, Y | 1 |
| Xi, J | 1 |
| Li, C | 1 |
| Chen, W | 3 |
| Hu, X | 2 |
| Zhang, F | 3 |
| Wei, H | 1 |
| Gurzu, S | 1 |
| Jung, I | 1 |
| Sugimura, H | 2 |
| Stefan-van Staden, RI | 1 |
| Yamada, H | 1 |
| Natsume, H | 1 |
| Iwashita, Y | 1 |
| Szodorai, R | 1 |
| Szederjesi, J | 1 |
| Yari, D | 1 |
| Ehsanbakhsh, Z | 1 |
| Validad, MH | 1 |
| Langroudi, FH | 1 |
| Esfandiari, H | 1 |
| Prager, A | 1 |
| Hassanpour, K | 1 |
| Kurup, SP | 1 |
| Mets-Halgrimson, R | 1 |
| Yoon, H | 1 |
| Zeid, JL | 1 |
| Mets, MB | 1 |
| Rahmani, B | 1 |
| Araujo-Castillo, RV | 1 |
| Culquichicón, C | 1 |
| Solis Condor, R | 1 |
| Efendi, F | 1 |
| Sebayang, SK | 1 |
| Astutik, E | 1 |
| Hadisuyatmana, S | 1 |
| Has, EMM | 1 |
| Kuswanto, H | 1 |
| Foroutan, T | 1 |
| Ahmadi, F | 1 |
| Moayer, F | 1 |
| Khalvati, S | 1 |
| Zhang, Q | 2 |
| Lyu, Y | 1 |
| Huang, J | 1 |
| Yu, N | 1 |
| Wen, Z | 1 |
| Hou, H | 1 |
| Zhao, T | 1 |
| Gupta, A | 1 |
| Khosla, N | 1 |
| Govindasamy, V | 1 |
| Saini, A | 1 |
| Annapurna, K | 1 |
| Dhakate, SR | 1 |
| Akkaya, Ö | 1 |
| Chandgude, AL | 1 |
| Dömling, A | 1 |
| Harnett, J | 1 |
| Oakes, K | 1 |
| Carè, J | 1 |
| Leach, M | 1 |
| Brown, D | 1 |
| Cramer, H | 1 |
| Pinder, TA | 1 |
| Steel, A | 1 |
| Anheyer, D | 1 |
| Cantu, J | 1 |
| Valle, J | 1 |
| Flores, K | 1 |
| Gonzalez, D | 1 |
| Valdes, C | 1 |
| Lopez, J | 1 |
| Padilla, V | 1 |
| Alcoutlabi, M | 1 |
| Parsons, J | 1 |
| Núñez, K | 1 |
| Hamed, M | 1 |
| Fort, D | 1 |
| Bruce, D | 1 |
| Thevenot, P | 1 |
| Cohen, A | 1 |
| Weber, P | 1 |
| Menezes, AMB | 1 |
| Gonçalves, H | 1 |
| Perez-Padilla, R | 1 |
| Jarvis, D | 1 |
| de Oliveira, PD | 1 |
| Wehrmeister, FC | 1 |
| Mir, S | 1 |
| Wong, J | 1 |
| Ryan, CM | 1 |
| Bellingham, G | 1 |
| Singh, M | 2 |
| Waseem, R | 1 |
| Eckert, DJ | 1 |
| Chung, F | 1 |
| Hegde, H | 1 |
| Shimpi, N | 1 |
| Panny, A | 1 |
| Glurich, I | 1 |
| Christie, P | 1 |
| Acharya, A | 1 |
| English, KL | 1 |
| Downs, M | 1 |
| Goetchius, E | 1 |
| Buxton, R | 1 |
| Ryder, JW | 1 |
| Ploutz-Snyder, R | 1 |
| Guilliams, M | 1 |
| Scott, JM | 1 |
| Ploutz-Snyder, LL | 1 |
| Martens, C | 1 |
| Goplen, FK | 1 |
| Aasen, T | 1 |
| Gjestad, R | 1 |
| Nordfalk, KF | 1 |
| Nordahl, SHG | 1 |
| Inoue, T | 1 |
| Soshi, S | 1 |
| Kubota, M | 1 |
| Marumo, K | 1 |
| Mortensen, NP | 1 |
| Caffaro, MM | 1 |
| Patel, PR | 2 |
| Uddin, MJ | 1 |
| Aravamudhan, S | 1 |
| Sumner, SJ | 1 |
| Fennell, TR | 1 |
| Gal, RL | 1 |
| Cohen, NJ | 1 |
| Kruger, D | 1 |
| Beck, RW | 1 |
| Bergenstal, RM | 1 |
| Calhoun, P | 1 |
| Cushman, T | 1 |
| Haban, A | 1 |
| Hood, K | 1 |
| Johnson, ML | 1 |
| McArthur, T | 1 |
| Olson, BA | 1 |
| Weinstock, RS | 1 |
| Oser, SM | 1 |
| Oser, TK | 1 |
| Bugielski, B | 1 |
| Strayer, H | 1 |
| Aleppo, G | 1 |
| Maruyama, H | 1 |
| Hirayama, K | 1 |
| Yamashita, M | 1 |
| Ohgi, K | 1 |
| Tsujimoto, R | 1 |
| Takayasu, M | 1 |
| Shimohata, H | 1 |
| Kobayashi, M | 1 |
| Buscagan, TM | 1 |
| Rees, DC | 1 |
| Jaborek, JR | 1 |
| Zerby, HN | 1 |
| Wick, MP | 1 |
| Fluharty, FL | 1 |
| Moeller, SJ | 1 |
| Razavi, P | 1 |
| Dickler, MN | 1 |
| Shah, PD | 1 |
| Toy, W | 1 |
| Brown, DN | 1 |
| Won, HH | 1 |
| Li, BT | 1 |
| Shen, R | 1 |
| Vasan, N | 1 |
| Modi, S | 1 |
| Jhaveri, K | 1 |
| Caravella, BA | 1 |
| Patil, S | 1 |
| Selenica, P | 1 |
| Zamora, S | 1 |
| Cowan, AM | 1 |
| Comen, E | 1 |
| Singh, A | 1 |
| Covey, A | 1 |
| Berger, MF | 1 |
| Hudis, CA | 1 |
| Norton, L | 1 |
| Nagy, RJ | 1 |
| Odegaard, JI | 1 |
| Lanman, RB | 1 |
| Solit, DB | 1 |
| Robson, ME | 1 |
| Lacouture, ME | 1 |
| Brogi, E | 1 |
| Reis-Filho, JS | 1 |
| Moynahan, ME | 1 |
| Scaltriti, M | 1 |
| Chandarlapaty, S | 1 |
| Papouskova, K | 1 |
| Moravcova, M | 1 |
| Masrati, G | 1 |
| Ben-Tal, N | 1 |
| Sychrova, H | 1 |
| Zimmermannova, O | 1 |
| Fang, J | 1 |
| Fan, Y | 1 |
| Luo, T | 2 |
| Su, H | 1 |
| Tsetseris, L | 1 |
| Anthopoulos, TD | 1 |
| Liu, SF | 1 |
| Zhao, K | 1 |
| Sacan, O | 1 |
| Turkyilmaz, IB | 1 |
| Bayrak, BB | 1 |
| Mutlu, O | 1 |
| Akev, N | 1 |
| Yanardag, R | 1 |
| Gruber, S | 1 |
| Kamnoedboon, P | 1 |
| Özcan, M | 1 |
| Srinivasan, M | 1 |
| Jo, YH | 1 |
| Oh, HK | 1 |
| Jeong, SY | 1 |
| Lee, BG | 1 |
| Zheng, J | 1 |
| Guan, H | 1 |
| Li, D | 3 |
| Tan, H | 1 |
| Maji, TK | 1 |
| J R, A | 1 |
| Mukherjee, S | 1 |
| Alexander, R | 1 |
| Mondal, A | 1 |
| Das, S | 1 |
| Sharma, RK | 1 |
| Chakraborty, NK | 1 |
| Dasgupta, K | 1 |
| Sharma, AMR | 1 |
| Hawaldar, R | 1 |
| Pandey, M | 1 |
| Naik, A | 1 |
| Majumdar, K | 1 |
| Pal, SK | 1 |
| Adarsh, KV | 1 |
| Ray, SK | 1 |
| Karmakar, D | 1 |
| Ma, Y | 2 |
| Gao, W | 1 |
| Ma, S | 1 |
| Lin, W | 1 |
| Zhou, T | 1 |
| Wu, T | 1 |
| Ye, C | 1 |
| He, X | 2 |
| Jiang, F | 1 |
| Yuan, D | 1 |
| Chen, Q | 1 |
| Hong, M | 1 |
| Chen, K | 1 |
| Hussain, M | 1 |
| Razi, SS | 1 |
| Yildiz, EA | 1 |
| Zhao, J | 1 |
| Yaglioglu, HG | 1 |
| Donato, MD | 1 |
| Jiang, J | 1 |
| Jamil, MI | 1 |
| Zhan, X | 1 |
| Chen, F | 1 |
| Cheng, D | 1 |
| Wu, CT | 1 |
| Utsunomiya, T | 1 |
| Ichii, T | 1 |
| Fujinami, S | 1 |
| Nakajima, K | 1 |
| Sanchez, DM | 1 |
| Raucci, U | 1 |
| Ferreras, KN | 1 |
| Martínez, TJ | 1 |
| Mordi, NA | 1 |
| Mordi, IR | 1 |
| Singh, JS | 1 |
| McCrimmon, RJ | 1 |
| Struthers, AD | 1 |
| Lang, CC | 1 |
| Wang, XW | 1 |
| Yuan, LJ | 1 |
| Yang, Y | 2 |
| Chen, WF | 1 |
| Luo, R | 1 |
| Yang, K | 1 |
| Amarasiri, SS | 1 |
| Attanayake, AP | 1 |
| Arawwawala, LDAM | 1 |
| Jayatilaka, KAPW | 1 |
| Mudduwa, LKB | 1 |
| Ogunsuyi, O | 2 |
| Akanni, O | 1 |
| Alabi, O | 1 |
| Alimba, C | 1 |
| Adaramoye, O | 1 |
| Cambier, S | 1 |
| Eswara, S | 1 |
| Gutleb, AC | 1 |
| Bakare, A | 1 |
| Gu, Z | 1 |
| Cong, J | 1 |
| Pellegrini, M | 1 |
| Palmieri, S | 1 |
| Ricci, A | 1 |
| Serio, A | 1 |
| Paparella, A | 1 |
| Lo Sterzo, C | 1 |
| Jadeja, SD | 1 |
| Vaishnav, J | 1 |
| Mansuri, MS | 1 |
| Shah, C | 1 |
| Mayatra, JM | 1 |
| Shah, A | 1 |
| Begum, R | 1 |
| Song, H | 2 |
| Lian, Y | 1 |
| Wan, T | 1 |
| Schultz-Lebahn, A | 1 |
| Skipper, MT | 1 |
| Hvas, AM | 1 |
| Larsen, OH | 1 |
| Hijazi, Z | 1 |
| Granger, CB | 1 |
| Hohnloser, SH | 1 |
| Westerbergh, J | 1 |
| Lindbäck, J | 1 |
| Alexander, JH | 1 |
| Keltai, M | 1 |
| Parkhomenko, A | 1 |
| López-Sendón, JL | 1 |
| Lopes, RD | 1 |
| Siegbahn, A | 1 |
| Wallentin, L | 1 |
| El-Tarabany, MS | 1 |
| Saleh, AA | 1 |
| El-Araby, IE | 1 |
| El-Magd, MA | 1 |
| van Ginkel, MPH | 1 |
| Schijven, MP | 1 |
| van Grevenstein, WMU | 1 |
| Schreuder, HWR | 1 |
| Pereira, EDM | 1 |
| da Silva, J | 1 |
| Carvalho, PDS | 1 |
| Grivicich, I | 1 |
| Picada, JN | 1 |
| Salgado Júnior, IB | 1 |
| Vasques, GJ | 1 |
| Pereira, MADS | 1 |
| Reginatto, FH | 1 |
| Ferraz, ABF | 1 |
| Vasilenko, EA | 1 |
| Gorshkova, EN | 1 |
| Astrakhantseva, IV | 1 |
| Drutskaya, MS | 1 |
| Tillib, SV | 1 |
| Nedospasov, SA | 1 |
| Mokhonov, VV | 1 |
| Nam, YW | 1 |
| Cui, M | 1 |
| Orfali, R | 1 |
| Viegas, A | 1 |
| Nguyen, M | 1 |
| Mohammed, EHM | 1 |
| Zoghebi, KA | 1 |
| Rahighi, S | 1 |
| Parang, K | 1 |
| Patterson, KC | 1 |
| Kahanovitch, U | 1 |
| Gonçalves, CM | 1 |
| Hablitz, JJ | 1 |
| Staruschenko, A | 1 |
| Mulkey, DK | 1 |
| Olsen, ML | 1 |
| Gu, L | 1 |
| Cao, X | 1 |
| Mukhtar, A | 1 |
| Wu, K | 1 |
| Zhang, YY | 1 |
| Zhu, Y | 1 |
| Lu, DZ | 1 |
| Dong, W | 1 |
| Bi, WJ | 1 |
| Feng, XJ | 1 |
| Wen, LM | 1 |
| Sun, H | 2 |
| Qi, MC | 1 |
| Chang, CC | 1 |
| Dinh, TK | 1 |
| Lee, YA | 1 |
| Wang, FN | 1 |
| Sung, YC | 1 |
| Yu, PL | 1 |
| Chiu, SC | 1 |
| Shih, YC | 1 |
| Wu, CY | 1 |
| Huang, YD | 1 |
| Lu, TT | 1 |
| Wan, D | 1 |
| Sakizadeh, J | 1 |
| Cline, JP | 1 |
| Snyder, MA | 1 |
| Kiely, CJ | 1 |
| McIntosh, S | 1 |
| Cao, JW | 1 |
| Zhao, CK | 1 |
| Yang, R | 1 |
| Zhang, QY | 1 |
| Chen, KJ | 2 |
| Liu, H | 2 |
| He, Z | 1 |
| Chen, B | 1 |
| Wu, J | 3 |
| Du, X | 1 |
| Moore, J | 1 |
| Blank, BR | 1 |
| Eksterowicz, J | 1 |
| Sutimantanapi, D | 1 |
| Yuen, N | 1 |
| Metzger, T | 1 |
| Chan, B | 1 |
| Huang, T | 1 |
| Chen, X | 1 |
| Duong, F | 1 |
| Kong, W | 1 |
| Chang, JH | 1 |
| Sun, J | 1 |
| Zavorotinskaya, T | 1 |
| Ye, Q | 1 |
| Junttila, MR | 1 |
| Ndubaku, C | 1 |
| Friedman, LS | 1 |
| Fantin, VR | 1 |
| Sun, D | 1 |
| Fei, P | 1 |
| Xie, Q | 1 |
| Jiang, Y | 1 |
| Feng, H | 1 |
| Chang, Y | 1 |
| Kang, H | 1 |
| Xing, M | 1 |
| Shao, Z | 1 |
| Yuan, C | 1 |
| Wu, Y | 1 |
| Allan, R | 1 |
| Canham, K | 1 |
| Wallace, R | 1 |
| Singh, D | 1 |
| Ward, J | 1 |
| Cooper, A | 1 |
| Newcomb, C | 1 |
| Nammour, S | 1 |
| El Mobadder, M | 1 |
| Maalouf, E | 1 |
| Namour, M | 1 |
| Namour, A | 1 |
| Rey, G | 1 |
| Matamba, P | 1 |
| Matys, J | 1 |
| Zeinoun, T | 1 |
| Grzech-Leśniak, K | 1 |
| Segabinazi Peserico, C | 1 |
| Garozi, L | 1 |
| Zagatto, AM | 1 |
| Machado, FA | 1 |
| Hirth, JM | 1 |
| Dinehart, EE | 1 |
| Lin, YL | 1 |
| Kuo, YF | 1 |
| Nouri, SS | 1 |
| Ritchie, C | 1 |
| Volow, A | 1 |
| Li, B | 2 |
| McSpadden, S | 1 |
| Dearman, K | 1 |
| Kotwal, A | 1 |
| Sudore, RL | 1 |
| Ward, L | 1 |
| Thakur, A | 1 |
| Kondadasula, SV | 1 |
| Ji, K | 1 |
| Schalk, DL | 1 |
| Bliemeister, E | 1 |
| Ung, J | 1 |
| Aboukameel, A | 1 |
| Casarez, E | 1 |
| Sloane, BF | 1 |
| Lum, LG | 1 |
| Xiao, M | 1 |
| Feng, X | 1 |
| Gao, R | 1 |
| Du, B | 1 |
| Brooks, T | 1 |
| Zwirner, J | 1 |
| Hammer, N | 1 |
| Ondruschka, B | 1 |
| Jermy, M | 1 |
| Luengo, A | 1 |
| Marzo, I | 1 |
| Reback, M | 1 |
| Daubit, IM | 1 |
| Fernández-Moreira, V | 1 |
| Metzler-Nolte, N | 1 |
| Gimeno, MC | 1 |
| Tonchev, I | 1 |
| Heberman, D | 1 |
| Peretz, A | 1 |
| Medvedovsky, AT | 1 |
| Gotsman, I | 1 |
| Rashi, Y | 1 |
| Poles, L | 1 |
| Goland, S | 1 |
| Perlman, GY | 1 |
| Danenberg, HD | 1 |
| Beeri, R | 1 |
| Shuvy, M | 1 |
| Fu, Q | 1 |
| Yang, D | 1 |
| Sarapulova, A | 1 |
| Pang, Q | 1 |
| Meng, Y | 1 |
| Wei, L | 1 |
| Ehrenberg, H | 1 |
| Kim, CC | 1 |
| Oh, KH | 1 |
| Nam, KT | 1 |
| Sun, JY | 1 |
| Ning, J | 1 |
| Duan, Z | 1 |
| Kershaw, SV | 1 |
| Rogach, AL | 1 |
| Gao, Z | 1 |
| Wang, T | 1 |
| Li, Q | 2 |
| Cao, T | 1 |
| Guo, L | 1 |
| Fu, Y | 1 |
| Seeger, ZL | 1 |
| Izgorodina, EI | 1 |
| Hue, S | 1 |
| Beldi-Ferchiou, A | 1 |
| Bendib, I | 1 |
| Surenaud, M | 1 |
| Fourati, S | 1 |
| Frapard, T | 1 |
| Rivoal, S | 1 |
| Razazi, K | 1 |
| Carteaux, G | 1 |
| Delfau-Larue, MH | 1 |
| Mekontso-Dessap, A | 1 |
| Audureau, E | 1 |
| de Prost, N | 1 |
| Gao, SS | 1 |
| Duangthip, D | 1 |
| Lo, ECM | 1 |
| Chu, CH | 1 |
| Roberts, W | 1 |
| Rosenheck, RA | 1 |
| Miyake, T | 1 |
| Kimoto, E | 1 |
| Luo, L | 1 |
| Mathialagan, S | 1 |
| Horlbogen, LM | 1 |
| Ramanathan, R | 1 |
| Wood, LS | 1 |
| Johnson, JG | 1 |
| Le, VH | 1 |
| Vourvahis, M | 1 |
| Rodrigues, AD | 1 |
| Muto, C | 1 |
| Furihata, K | 1 |
| Sugiyama, Y | 1 |
| Kusuhara, H | 1 |
| Gong, Q | 1 |
| Song, W | 1 |
| Sun, B | 1 |
| Cao, P | 1 |
| Gu, S | 2 |
| Sun, X | 2 |
| Zhou, G | 1 |
| Toma, C | 1 |
| Khandhar, S | 1 |
| Zalewski, AM | 1 |
| D'Auria, SJ | 1 |
| Tu, TM | 1 |
| Jaber, WA | 1 |
| Cho, J | 2 |
| Suwandaratne, NS | 1 |
| Razek, S | 1 |
| Choi, YH | 1 |
| Piper, LFJ | 1 |
| Watson, DF | 1 |
| Banerjee, S | 1 |
| Xie, S | 1 |
| Lindsay, AP | 1 |
| Bates, FS | 1 |
| Lodge, TP | 1 |
| Hao, Y | 1 |
| Chapovetsky, A | 1 |
| Liu, JJ | 1 |
| Welborn, M | 1 |
| Luna, JM | 1 |
| Do, T | 1 |
| Haiges, R | 1 |
| Miller Iii, TF | 1 |
| Marinescu, SC | 1 |
| Lopez, SA | 1 |
| Compter, I | 1 |
| Eekers, DBP | 1 |
| Hoeben, A | 1 |
| Rouschop, KMA | 1 |
| Reymen, B | 1 |
| Ackermans, L | 1 |
| Beckervordersantforth, J | 1 |
| Bauer, NJC | 1 |
| Anten, MM | 1 |
| Wesseling, P | 1 |
| Postma, AA | 1 |
| De Ruysscher, D | 1 |
| Lambin, P | 1 |
| Qiang, L | 1 |
| Yang, S | 1 |
| Cui, YH | 1 |
| He, YY | 1 |
| Kumar, SK | 1 |
| Jacobus, SJ | 1 |
| Cohen, AD | 1 |
| Weiss, M | 1 |
| Callander, N | 1 |
| Singh, AK | 1 |
| Parker, TL | 1 |
| Menter, A | 1 |
| Parsons, B | 1 |
| Kumar, P | 1 |
| Kapoor, P | 1 |
| Rosenberg, A | 1 |
| Zonder, JA | 1 |
| Faber, E | 1 |
| Lonial, S | 1 |
| Anderson, KC | 1 |
| Richardson, PG | 1 |
| Orlowski, RZ | 1 |
| Wagner, LI | 1 |
| Rajkumar, SV | 1 |
| Li, G | 1 |
| Hou, G | 1 |
| Cui, J | 1 |
| Xie, H | 1 |
| Sun, Z | 1 |
| Fang, Z | 1 |
| Dunstand-Guzmán, E | 1 |
| Hallal-Calleros, C | 1 |
| Hernández-Velázquez, VM | 1 |
| Canales-Vargas, EJ | 1 |
| Domínguez-Roldan, R | 1 |
| Pedernera, M | 1 |
| Peña-Chora, G | 1 |
| Flores-Pérez, I | 1 |
| Kim, MJ | 2 |
| Han, C | 1 |
| White, K | 1 |
| Park, HJ | 1 |
| Ding, D | 1 |
| Boyd, K | 1 |
| Rothenberger, C | 1 |
| Bose, U | 1 |
| Carmichael, P | 1 |
| Linser, PJ | 1 |
| Tanokura, M | 1 |
| Salvi, R | 1 |
| Someya, S | 1 |
| Samuni, A | 1 |
| Goldstein, S | 1 |
| Divya, KP | 1 |
| Dharuman, V | 1 |
| Feng, J | 2 |
| Qian, Y | 1 |
| Cheng, Q | 1 |
| Ma, H | 1 |
| Ren, X | 1 |
| Wei, Q | 1 |
| Pan, W | 1 |
| Guo, J | 1 |
| Situ, B | 1 |
| An, T | 1 |
| Zheng, L | 1 |
| Augusto, S | 1 |
| Ratola, N | 1 |
| Tarín-Carrasco, P | 1 |
| Jiménez-Guerrero, P | 1 |
| Turco, M | 1 |
| Schuhmacher, M | 1 |
| Costa, S | 1 |
| Teixeira, JP | 1 |
| Costa, C | 1 |
| Syed, A | 1 |
| Marraiki, N | 1 |
| Al-Rashed, S | 1 |
| Elgorban, AM | 1 |
| Yassin, MT | 1 |
| Chankhanittha, T | 1 |
| Nanan, S | 1 |
| Sorokina, KN | 1 |
| Samoylova, YV | 1 |
| Gromov, NV | 1 |
| Ogorodnikova, OL | 1 |
| Parmon, VN | 1 |
| Ye, J | 1 |
| Liao, W | 1 |
| Zhang, P | 1 |
| Nabi, M | 1 |
| Cai, Y | 1 |
| Li, F | 1 |
| Alsbou, EM | 1 |
| Omari, KW | 1 |
| Adeosun, WA | 1 |
| Asiri, AM | 1 |
| Marwani, HM | 1 |
| Barral, M | 1 |
| Jemal-Turki, A | 1 |
| Beuvon, F | 1 |
| Soyer, P | 1 |
| Camparo, P | 1 |
| Cornud, F | 1 |
| Atwater, BD | 1 |
| Jones, WS | 1 |
| Loring, Z | 1 |
| Friedman, DJ | 1 |
| Namburath, M | 1 |
| Papirio, S | 1 |
| Moscariello, C | 1 |
| Di Costanzo, N | 1 |
| Pirozzi, F | 1 |
| Alappat, BJ | 1 |
| Sreekrishnan, TR | 1 |
| Volpin, F | 1 |
| Woo, YC | 1 |
| Kim, H | 2 |
| Freguia, S | 1 |
| Jeong, N | 1 |
| Choi, JS | 1 |
| Phuntsho, S | 1 |
| Shon, HK | 1 |
| Domínguez-Zambrano, E | 1 |
| Pedraza-Chaverri, J | 1 |
| López-Santos, AL | 1 |
| Medina-Campos, ON | 1 |
| Cruz-Rivera, C | 1 |
| Bueno-Hernández, F | 1 |
| Espinosa-Cuevas, A | 1 |
| Bulavaitė, A | 1 |
| Dalgediene, I | 1 |
| Michailoviene, V | 1 |
| Pleckaityte, M | 1 |
| Sauerbier, P | 1 |
| Köhler, R | 1 |
| Renner, G | 1 |
| Militz, H | 1 |
| Bukovsky, A | 1 |
| Xiong, H | 1 |
| Huang, L | 1 |
| Mao, T | 1 |
| Yang, L | 2 |
| Huang, D | 1 |
| Yu, J | 2 |
| Shu, Y | 1 |
| Xia, K | 1 |
| Su, T | 1 |
| Henriques Abreu, M | 1 |
| Bartosch, C | 1 |
| Liang, Y | 1 |
| Tian, R | 1 |
| Shan, Y | 1 |
| Gao, H | 1 |
| Xie, C | 1 |
| Xu, M | 1 |
| Bragagnoli, AC | 1 |
| Araujo, RLC | 1 |
| Ferraz, MW | 1 |
| Dos Santos, LV | 1 |
| Abdalla, KC | 1 |
| Comar, F | 1 |
| Santos, FA | 1 |
| Oliveira, MA | 1 |
| Carvalheira, JBC | 1 |
| Cárcano, FM | 1 |
| da Silveira Nogueira Lima, JP | 1 |
| Huynh, LM | 1 |
| Keit, E | 1 |
| Huang, E | 1 |
| Carrillo, RC | 1 |
| Ahlering, TE | 1 |
| Boyle, S | 1 |
| Enke, CA | 1 |
| Baine, M | 1 |
| Cho, WR | 1 |
| Wang, CC | 1 |
| Tsai, MY | 1 |
| Chou, CK | 1 |
| Liu, YW | 1 |
| Wu, YJ | 1 |
| Lin, MT | 1 |
| Chen, KD | 1 |
| Chuang, CH | 1 |
| Huang, PY | 1 |
| Hu, TH | 1 |
| Tsai, MC | 1 |
| Morio, K | 1 |
| Kurata, Y | 1 |
| Kawaguchi-Sakita, N | 1 |
| Shiroshita, A | 1 |
| Kataoka, Y | 1 |
| Porper, K | 1 |
| Shpatz, Y | 1 |
| Plotkin, L | 1 |
| Pechthold, RG | 1 |
| Talianski, A | 1 |
| Champ, CE | 1 |
| Furman, O | 1 |
| Shimoni-Sebag, A | 1 |
| Symon, Z | 1 |
| Amit, U | 1 |
| Hemi, R | 1 |
| Kanety, H | 1 |
| Mardor, Y | 1 |
| Cohen, ZR | 1 |
| Jan, E | 1 |
| Genssin, H | 1 |
| Anikster, Y | 1 |
| Zach, L | 1 |
| Lawrence, YR | 1 |
| Gash, KJ | 1 |
| Chambers, AC | 1 |
| Cotton, DE | 1 |
| Williams, AC | 1 |
| Thomas, MG | 1 |
| Henderson, D | 1 |
| Frieson, D | 1 |
| Zuber, J | 1 |
| Solomon, SS | 1 |
| Fransgaard, T | 2 |
| Thygesen, LC | 2 |
| Gögenur, I | 2 |
| Xu, T | 1 |
| Qiao, M | 1 |
| Kang, WH | 1 |
| Tak, E | 1 |
| Hwang, S | 1 |
| Song, GW | 1 |
| Jwa, E | 1 |
| Lee, YJ | 1 |
| Kim, KH | 1 |
| Ahn, CS | 1 |
| Moon, DB | 1 |
| Ha, TY | 1 |
| Jung, DH | 1 |
| Park, GC | 1 |
| Lee, KJ | 1 |
| Kim, N | 1 |
| Lee, SG | 1 |
| Yang, Q | 2 |
| Guo, X | 1 |
| Chu, D | 1 |
| Wang, K | 1 |
| Zhao, M | 1 |
| Li, L | 1 |
| Guo, R | 1 |
| Insin, P | 1 |
| Prueksaritanond, N | 1 |
| Kubo, T | 1 |
| Ninomiya, T | 1 |
| Hotta, K | 1 |
| Kozuki, T | 1 |
| Toyooka, S | 1 |
| Okada, H | 1 |
| Fujiwara, T | 1 |
| Udono, H | 1 |
| Kiura, K | 1 |
| Ramos-Peñafiel, C | 1 |
| Olarte-Carrillo, I | 1 |
| Cerón-Maldonado, R | 1 |
| Rozen-Fuller, E | 1 |
| Kassack-Ipiña, JJ | 1 |
| Meléndez-Mier, G | 1 |
| Collazo-Jaloma, J | 1 |
| Martínez-Tovar, A | 1 |
| Saka Herrán, C | 1 |
| Jané-Salas, E | 1 |
| Estrugo Devesa, A | 1 |
| López-López, J | 1 |
| Aminsharifi, A | 1 |
| Howard, LE | 1 |
| Amling, CL | 2 |
| Aronson, WJ | 2 |
| Cooperberg, MR | 2 |
| Kane, CJ | 2 |
| Terris, MK | 2 |
| Polascik, TJ | 1 |
| Freedland, SJ | 2 |
| Lee, BB | 1 |
| Kim, D | 1 |
| Cho, EY | 1 |
| Han, J | 1 |
| Kim, HK | 1 |
| Shim, YM | 1 |
| Kim, DH | 1 |
| Hallas, J | 1 |
| Yong, C | 1 |
| Dan, L | 1 |
| Chenhong, L | 1 |
| Yan, S | 1 |
| Jianfei, C | 1 |
| Jianlong, G | 1 |
| De, A | 1 |
| Kuppusamy, G | 1 |
| Park, JH | 1 |
| Park, EH | 1 |
| Lee, SJ | 2 |
| Kim, A | 1 |
| Shim, S | 1 |
| Jang, H | 1 |
| Myung, JK | 1 |
| Strickler, HD | 1 |
| Kaushik, D | 1 |
| Karnes, RJ | 1 |
| Eisenberg, MS | 1 |
| Rangel, LJ | 1 |
| Carlson, RE | 1 |
| Bergstralh, EJ | 1 |
| Gadéa, É | 1 |
| Thivat, É | 1 |
| Wang-Lopez, Q | 1 |
| Viala, M | 1 |
| Paulon, R | 1 |
| Planchat, É | 1 |
| Chadeyras, JB | 1 |
| Merlin, C | 1 |
| Coudert, B | 1 |
| Bignon, YJ | 1 |
| Morio, B | 1 |
| Durando, X | 1 |
| Rieken, M | 4 |
| Xylinas, E | 3 |
| Kluth, L | 3 |
| Crivelli, JJ | 2 |
| Chrystal, J | 2 |
| Faison, T | 2 |
| Lotan, Y | 3 |
| Karakiewicz, PI | 3 |
| Fajkovic, H | 3 |
| Babjuk, M | 2 |
| Kautzky-Willer, A | 2 |
| Bachmann, A | 3 |
| Scherr, DS | 3 |
| Shariat, SF | 4 |
| Allott, EH | 1 |
| Abern, MR | 1 |
| Gerber, L | 1 |
| Keto, CJ | 1 |
| Moorman, PG | 1 |
| Trinh, QD | 1 |
| Lee, RK | 1 |
| Novara, G | 1 |
| Margulis, V | 1 |
| Martinez-Salamanca, JI | 1 |
| Matsumoto, K | 1 |
| Seitz, C | 1 |
| Remzi, M | 1 |
| Briganti, A | 1 |
| Skinner, HD | 1 |
| Crane, CH | 1 |
| Garrett, CR | 1 |
| Eng, C | 1 |
| Chang, GJ | 1 |
| Skibber, JM | 1 |
| Rodriguez-Bigas, MA | 1 |
| Kelly, P | 1 |
| Sandulache, VC | 1 |
| Delclos, ME | 1 |
| Krishnan, S | 1 |
| Das, P | 1 |
| Sun, M | 1 |
| Cresswell, J | 1 |
| Nangia-Makker, P | 1 |
| Yu, Y | 1 |
| Vasudevan, A | 1 |
| Farhana, L | 1 |
| Rajendra, SG | 1 |
| Levi, E | 1 |
| Majumdar, AP | 1 |
| Opdam, FL | 1 |
| Huitema, AD | 1 |
| Beijnen, JH | 1 |
| Schellens, JH | 1 |
| Danzig, MR | 1 |
| Kotamarti, S | 1 |
| Ghandour, RA | 1 |
| Rothberg, MB | 1 |
| Dubow, BP | 1 |
| Benson, MC | 1 |
| Badani, KK | 1 |
| McKiernan, JM | 1 |
| Jiao, J | 1 |
| Deng, Y | 1 |
| Sestak, I | 1 |
| Cuzick, J | 1 |
| Yu, H | 1 |
| Yin, L | 1 |
| Tian, H | 1 |
| Gao, X | 1 |
| Hwang, IC | 1 |
| Park, SM | 1 |
| Shin, D | 1 |
| Ahn, HY | 1 |
| Deng, D | 1 |
| Skrip, L | 1 |
| Kwon, M | 1 |
| Roh, JL | 1 |
| Lee, SW | 1 |
| Kim, SB | 1 |
| Choi, SH | 1 |
| Nam, SY | 1 |
| Calip, GS | 1 |
| Yu, O | 1 |
| Hoskins, KF | 1 |
| Boudreau, DM | 1 |
| Kong, F | 1 |
| Zheng, R | 1 |
| Liu, G | 1 |
| Jia, Y | 1 |
| Winters, B | 1 |
| Plymate, S | 1 |
| Zeliadt, SB | 1 |
| Holt, S | 1 |
| Hu, E | 1 |
| Lin, DW | 1 |
| Morrissey, C | 1 |
| Wooldridge, B | 1 |
| Gore, JL | 1 |
| Porter, MP | 1 |
| Wright, JL | 1 |
| Ge, R | 1 |
| Wu, S | 1 |
| Zhuo, Y | 1 |
| Otsetov, AG | 1 |
| Cai, C | 1 |
| Zhong, W | 1 |
| Wu, CL | 1 |
| Olumi, AF | 1 |
| Sato, Y | 1 |
| Kiyokawa, T | 1 |
| Koshizaka, M | 1 |
| Hanaoka, H | 1 |
| Shozu, M | 1 |
| Hall, C | 1 |
| Gehlot, A | 1 |
| Zorn, KK | 1 |
| Burnett, AF | 1 |
| Ezewuiro, O | 1 |
| Grushko, TA | 1 |
| Kocherginsky, M | 1 |
| Habis, M | 1 |
| Hurteau, JA | 1 |
| Mills, KA | 1 |
| Hunn, J | 1 |
| Olopade, OI | 1 |
| Fleming, GF | 1 |
| Romero, IL | 1 |
| McNamara, MG | 1 |
| Aneja, P | 1 |
| Le, LW | 1 |
| Horgan, AM | 1 |
| McKeever, E | 1 |
| Knox, JJ | 1 |
| Higurashi, T | 1 |
| Hosono, K | 1 |
| Takahashi, H | 1 |
| Komiya, Y | 1 |
| Umezawa, S | 1 |
| Sakai, E | 1 |
| Uchiyama, T | 1 |
| Taniguchi, L | 1 |
| Hata, Y | 1 |
| Uchiyama, S | 1 |
| Hattori, A | 1 |
| Nagase, H | 1 |
| Kessoku, T | 1 |
| Arimoto, J | 1 |
| Matsuhashi, N | 1 |
| Inayama, Y | 1 |
| Yamanaka, S | 1 |
| Taguri, M | 1 |
| Nakajima, A | 1 |
| You, A | 1 |
| Cao, M | 1 |
| Guo, Z | 1 |
| Zuo, B | 1 |
| Gao, J | 1 |
| Zhou, H | 1 |
| Fang, F | 1 |
| Zhang, W | 1 |
| Song, T | 1 |
| Zhu, X | 1 |
| Yin, H | 1 |
| Medairos, RA | 1 |
| Clark, J | 1 |
| Holoubek, S | 1 |
| Kubasiak, JC | 1 |
| Pithadia, R | 1 |
| Hamid, F | 1 |
| Chmielewski, GW | 1 |
| Warren, WH | 1 |
| Basu, S | 1 |
| Borgia, JA | 1 |
| Liptay, MJ | 1 |
| Seder, CW | 1 |
| Seebacher, V | 1 |
| Bergmeister, B | 1 |
| Grimm, C | 1 |
| Koelbl, H | 1 |
| Reinthaller, A | 1 |
| Polterauer, S | 1 |
| Joentausta, RM | 1 |
| Kujala, PM | 1 |
| Visakorpi, T | 1 |
| Tammela, TL | 1 |
| Murtola, TJ | 1 |
| Ahn, JH | 1 |
| Jung, SI | 1 |
| Yim, SU | 1 |
| Kim, SW | 1 |
| Hwang, EC | 1 |
| Kwon, DD | 1 |
| Shen, C | 1 |
| Peng, C | 1 |
| Shen, B | 1 |
| Zhu, Z | 1 |
| Xu, N | 1 |
| Li, T | 1 |
| Xie, J | 1 |
| Zimmermann, M | 1 |
| Arachchige-Don, AP | 1 |
| Donaldson, MS | 1 |
| Patriarchi, T | 1 |
| Horne, MC | 1 |
| Chan, KM | 1 |
| Kuo, CF | 1 |
| Hsu, JT | 1 |
| Chiou, MJ | 1 |
| Wang, YC | 1 |
| Wu, TH | 1 |
| Lee, CF | 1 |
| Wu, TJ | 1 |
| Chou, HS | 1 |
| Lee, WC | 1 |
| Singh, PP | 1 |
| Shi, Q | 1 |
| Foster, NR | 1 |
| Grothey, A | 1 |
| Nair, SG | 1 |
| Chan, E | 1 |
| Shields, AF | 1 |
| Goldberg, RM | 1 |
| Gill, S | 1 |
| Kahlenberg, MS | 1 |
| Sinicrope, FA | 1 |
| Sargent, DJ | 1 |
| Alberts, SR | 1 |
| Lerner, MZ | 1 |
| Mor, N | 1 |
| Paek, H | 1 |
| Blitzer, A | 1 |
| Strome, M | 1 |
| Han, MS | 1 |
| Park, SJ | 1 |
| Hong, SP | 1 |
| Cheon, JH | 1 |
| Kim, WH | 1 |
| Kim, TI | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer[NCT01101438] | Phase 3 | 3,649 participants (Actual) | Interventional | 2010-08-13 | Completed | ||
| The Possible Effect of Itraconazole as add-on Therapy to Paclitaxel and Carboplatin on the Treatment Outcome in Patients With Advanced Ovarian Cancer[NCT05591560] | 66 participants (Anticipated) | Interventional | 2022-10-31 | Not yet recruiting | |||
| An Open-Label Single-Arm Phase Ⅱ Study to Evaluate Efficacy and Safety of Sintilimab Combined With Metformin Hydrochloride in Patients With Advanced Non-small Cell Lung Cancer Refractory to First-Line Treatment[NCT03874000] | Phase 2 | 43 participants (Anticipated) | Interventional | 2019-03-08 | Recruiting | ||
| Effect of the Addition of Metformin Hydrochloride on the Prognosis of Patients With B-cell Precursor (Ph+ Negative) Acute Lymphoblastic Leukemia With High Expression of ABCB1 Gene[NCT03118128] | 102 participants (Actual) | Interventional | 2015-01-01 | Completed | |||
| The Effects of Neoadjuvant Metformin on Tumour Cell Proliferation and Tumour Progression in Pancreatic Ductal Adenocarcinoma[NCT02978547] | Phase 2 | 20 participants (Anticipated) | Interventional | 2019-01-31 | Not yet recruiting | ||
| Celebrex and Metformin for Postoperative Hepatocellular Carcinoma[NCT03184493] | Phase 3 | 200 participants (Anticipated) | Interventional | 2017-06-02 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Patients who died from breast cancer (NCT01101438)
Timeframe: 10 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm I | 155 |
| Arm II | 160 |
Distant Relapse Free Survival (DRFS) is defined as the percentage of patients without any documented distant recurrence, death from breast cancer, death from a non breast cancer cause or death from an unknown cause. If a subject has not had distant DRFS event nor died at the time of data cut-off for this analysis, DRFS will be censored on the date of last disease assessment. (NCT01101438)
Timeframe: 5 years
| Intervention | percentage of patients without event (Number) |
|---|---|
| Metformin | 88.7 |
| Placebo | 87.8 |
Invasive disease-free survival (IDFS) is defined as the percent of patients without documented development of ipsilateral and contralateral invasive breast tumour, local/regional invasive recurrence, distant recurrence, death from any causes. If a subject has not had invasive disease or died at the time of data cut-off for this final analysis, IDFS was censored on the date of last follow-up. (NCT01101438)
Timeframe: 5 years
| Intervention | percentage of patients without event (Number) |
|---|---|
| Metformin | 84.9 |
| Placebo | 84.1 |
Invasive disease-free survival (IDFS) is defined as percentage of patients without documented development of ipsilateral and contralateral invasive breast tumour, local/regional invasive recurrence, distant recurrence, death from any causes. If a subject has not had invasive disease or died at the time of data cut-off for this final analysis, IDFS was censored on the date of last follow-up. (NCT01101438)
Timeframe: 5 years
| Intervention | percentage of patients without event (Number) |
|---|---|
| Metformin | 86.5 |
| Placebo | 85.9 |
17 reviews available for metformin and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Outcomes of women treated with progestin and metformin for atypical endometrial hyperplasia and early endometrial cancer: a systematic review and meta-analysis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Endometrial Hyperplasia; Endometrial Neoplasm | 2021 |
Metformin: A Promising Radiosensitizer in Neoadjuvant Rectal Cancer Treatment.
Topics: Chemoradiotherapy; Humans; Metformin; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Stag | 2023 |
Progestin plus metformin improves outcomes in patients with endometrial hyperplasia and early endometrial cancer more than progestin alone: a meta-analysis.
Topics: Endometrial Hyperplasia; Endometrial Neoplasms; Female; Fertility Preservation; Humans; Metformin; N | 2023 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Immunology of tissue homeostasis, ovarian cancer growth and regression, and long lasting cancer immune prophylaxis - review of literature.
Topics: Animals; Autoantibodies; Bees; Carcinoma, Ovarian Epithelial; Cell Proliferation; Female; Homeostasi | 2021 |
Recycling the Purpose of Old Drugs to Treat Ovarian Cancer.
Topics: Diphosphonates; Drug Repositioning; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; | 2020 |
Efficacy of Metformin in Patients With Breast Cancer Receiving Chemotherapy or Endocrine Therapy: Systematic Review and Meta-analysis.
Topics: Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Metformin; Neoadjuvant Therapy; Neoplasm R | 2022 |
Potentiating the effects of radiotherapy in rectal cancer: the role of aspirin, statins and metformin as adjuncts to therapy.
Topics: Aspirin; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Female; Humans; H | 2017 |
Effect of metformin use on the risk and prognosis of endometrial cancer: a systematic review and meta-analysis.
Topics: Endometrial Neoplasms; Female; Humans; Hypoglycemic Agents; Metformin; Neoplasm Recurrence, Local; O | 2018 |
Protective effects of metformin, statins and anti-inflammatory drugs on head and neck cancer: A systematic review.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Case-Control Studies; Cohort Studi | 2018 |
Metformin in breast cancer: preclinical and clinical evidence.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Chemoth | 2020 |
Obesity and its impact on breast cancer: tumor incidence, recurrence, survival, and possible interventions.
Topics: Breast Neoplasms; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Metformin; Neoplas | 2013 |
Synergism between metformin and statins in modifying the risk of biochemical recurrence following radical prostatectomy in men with diabetes.
Topics: Aged; Clinical Trials as Topic; Diabetes Complications; Disease-Free Survival; Drug Synergism; Human | 2015 |
Update on breast cancer risk prediction and prevention.
Topics: Age of Onset; Aromatase Inhibitors; Aspirin; Biomarkers, Tumor; Breast Neoplasms; Diphosphonates; Fe | 2015 |
Effect of metformin on cancer risk and treatment outcome of prostate cancer: a meta-analysis of epidemiological observational studies.
Topics: Humans; Male; Metformin; Neoplasm Recurrence, Local; Prostatic Neoplasms; Publication Bias; Risk Fac | 2014 |
Metformin association with lower prostate cancer recurrence in type 2 diabetes: a systematic review and meta-analysis.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Male; Metformin; Neoplasm Recurrence, Local; | 2015 |
Association between metformin therapy and incidence, recurrence and mortality of prostate cancer: evidence from a meta-analysis.
Topics: Aged; Anticarcinogenic Agents; Diabetes Complications; Diabetes Mellitus, Type 2; Evidence-Based Med | 2015 |
11 trials available for metformin and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical Trial.
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast | 2022 |
A phase I trial of metformin in combination with vincristine, irinotecan, and temozolomide in children with relapsed or refractory solid and central nervous system tumors: A report from the national pediatric cancer foundation.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Central Nervous System Neo | 2023 |
Beyond diabetes mellitus: role of metformin in non-muscle-invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; BCG Vaccine; Diabetes Mellitus; Disease Progre | 2022 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Metformin plus lrinotecan in patients with refractory colorectal cancer: a phase 2 clinical trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Follow-Up | 2021 |
Impact of metformin use on the recurrence of hepatocellular carcinoma after initial liver resection in diabetic patients.
Topics: Aged; Carcinoma, Hepatocellular; Diabetes Mellitus; Female; Follow-Up Studies; Humans; Liver; Liver | 2021 |
A Phase I clinical trial of dose-escalated metabolic therapy combined with concomitant radiation therapy in high-grade glioma.
Topics: Brain Neoplasms; Combined Modality Therapy; Glioma; Humans; Ketones; Metformin; Middle Aged; Neoplas | 2021 |
Study Protocol: Phase-Ib Trial of Nivolumab Combined With Metformin for Refractory/Recurrent Solid Tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Comb | 2018 |
Effect of metformin on the survival of patients with ALL who express high levels of the ABCB1 drug resistance gene.
Topics: Adolescent; Adult; ATP Binding Cassette Transporter, Subfamily B; Drug Resistance, Neoplasm; Female; | 2018 |
Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer.
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Endometrial | 2016 |
Metformin for chemoprevention of metachronous colorectal adenoma or polyps in post-polypectomy patients without diabetes: a multicentre double-blind, placebo-controlled, randomised phase 3 trial.
Topics: Adenoma; Adult; Aged; Aged, 80 and over; Chemoprevention; Colonic Polyps; Colonoscopy; Colorectal Ne | 2016 |
60 other studies available for metformin and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Lasting Complete Clinical Response of a Recurring Cutaneous Squamous Cell Carcinoma With
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Class I Phosphatidylinositol 3-Kinases; Drug | 2022 |
A role for metformin in the treatment of Dupuytren disease?
Topics: Cells, Cultured; Dupuytren Contracture; Fibroblasts; Fibrosis; Humans; Metformin; Neoplasm Recurrenc | 2022 |
Synergic Effect of Metformin and Everolimus on Mitochondrial Dynamics of Renal Cell Carcinoma.
Topics: Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Everolimus; Humans; Kidney Neoplasms; M | 2022 |
Metformin administration is associated with enhanced response to transarterial chemoembolization for hepatocellular carcinoma in type 2 diabetes patients.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Diabetes Mellitus, Type 2; Humans; Liver | 2022 |
The effect of non-oncology drugs on clinical and genomic risk in early luminal breast cancer.
Topics: Breast Neoplasms; Female; Genomics; Humans; Metformin; Neoplasm Recurrence, Local; Thyroxine | 2022 |
The effect of non-oncology drugs on clinical and genomic risk in early luminal breast cancer.
Topics: Breast Neoplasms; Female; Genomics; Humans; Metformin; Neoplasm Recurrence, Local; Thyroxine | 2022 |
The effect of non-oncology drugs on clinical and genomic risk in early luminal breast cancer.
Topics: Breast Neoplasms; Female; Genomics; Humans; Metformin; Neoplasm Recurrence, Local; Thyroxine | 2022 |
The effect of non-oncology drugs on clinical and genomic risk in early luminal breast cancer.
Topics: Breast Neoplasms; Female; Genomics; Humans; Metformin; Neoplasm Recurrence, Local; Thyroxine | 2022 |
Prognostic Relevance of Type 2 Diabetes and Metformin Treatment in Head and Neck Melanoma: Results from a Population-Based Cohort Study.
Topics: Cohort Studies; Diabetes Mellitus, Type 2; Head and Neck Neoplasms; Humans; Melanoma; Metformin; Neo | 2022 |
The Antineoplastic Effect of Carboplatin Is Potentiated by Combination with Pitavastatin or Metformin in a Chemoresistant High-Grade Serous Carcinoma Cell Line.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cell | 2022 |
Trends and characteristics of fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer in Japan: a survey by the Gynecologic Oncology Committee of the Japan Society of Obstetrics and Gynecology.
Topics: Carcinoma, Endometrioid; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Fertility Preservat | 2023 |
Post-diagnostic metformin and statin use and risk of biochemical recurrence in Veterans diagnosed with prostate cancer.
Topics: Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metformin; Neoplasm Recurrence, Local; | 2023 |
Metformin sensitizes AML cells to venetoclax through endoplasmic reticulum stress-CHOP pathway.
Topics: Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Endoplasmic Reticulum Stress; | 2023 |
STAT3/LKB1 controls metastatic prostate cancer by regulating mTORC1/CREB pathway.
Topics: AMP-Activated Protein Kinases; Animals; Diabetes Mellitus, Type 2; Humans; Male; Mechanistic Target | 2023 |
Survival advantage associated with metformin usage in hepatocellular carcinoma patients with diabetes mellitus receiving radical resection: a propensity score matching analysis.
Topics: Carcinoma, Hepatocellular; China; Diabetes Mellitus; Disease-Free Survival; Hepatectomy; Humans; Liv | 2020 |
The Postoperative Occurrence or Worsening of Diabetes Mellitus May Increase the Risk of Recurrence in Resected Pancreatic Neuroendocrine Tumors.
Topics: Adult; Aged; Diabetes Mellitus; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Male; Metfor | 2020 |
The addition of metformin to progestin therapy in the fertility-sparing treatment of women with atypical hyperplasia/endometrial intraepithelial neoplasia or endometrial cancer: Little impact on response and low live-birth rates.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma in Situ; Cohort Studies; Endometria | 2020 |
The effect of metformin on the risk of recurrent nonmelanoma skin cancers.
Topics: Carcinoma, Basal Cell; Humans; Metformin; Neoplasm Recurrence, Local; Skin Neoplasms | 2020 |
Diabetes and Metformin Association with Recurrence Score in a Large Oncotype Database of Breast Cancer Patients.
Topics: Adolescent; Adult; Aged; Breast Neoplasms; Comorbidity; Databases, Factual; Diabetes Mellitus, Type | 2020 |
Metformin reduces the increased risk of oral squamous cell carcinoma recurrence in patients with type 2 diabetes mellitus: A cohort study with propensity score analyses.
Topics: Carcinoma, Squamous Cell; China; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Humans; Hypog | 2020 |
Melanotic neuroectodermal tumor of infancy successfully treated with metformin: A case report.
Topics: Combined Modality Therapy; Female; Humans; Hypoglycemic Agents; Infant; Magnetic Resonance Imaging; | 2020 |
Protective Effects of Metformin Against Biochemical Failure Following Radical Prostatectomy or Radiation Therapy in Localized Prostate Cancer.
Topics: Aged; Follow-Up Studies; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Neoplasm Grading | 2021 |
Metformin Has Positive Therapeutic Effects in Colon Cancer and Lung Cancer.
Topics: Aged; Antineoplastic Agents; Cohort Studies; Colonic Neoplasms; Diabetes Mellitus, Type 2; Disease-F | 2017 |
Association between metformin use after surgery for colorectal cancer and oncological outcomes: A nationwide register-based study.
Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Diabetes Mellitus, Type 2; Disease-Free Surviv | 2018 |
Prognostic value of metformin for non-small cell lung cancer patients with diabetes.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Diabetes Mellitus, Type 2; Female; F | 2018 |
Metformin-associated Chemopreventive Effects on Recurrence After Hepatic Resection of Hepatocellular Carcinoma: From
Topics: Aged; Animals; Carcinoma, Hepatocellular; Case-Control Studies; Cell Line, Tumor; Chemoprevention; C | 2018 |
Metformin Enhances the Effect of Regorafenib and Inhibits Recurrence and Metastasis of Hepatic Carcinoma After Liver Resection via Regulating Expression of Hypoxia Inducible Factors 2α (HIF-2α) and 30 kDa HIV Tat-Interacting Protein (TIP30).
Topics: Acetyltransferases; Animals; Apoptosis; Basic Helix-Loop-Helix Transcription Factors; Carcinoma, Hep | 2018 |
Therapeutic Use of Metformin in Diabetes and Survival Outcomes in Endometrial Cancer Patients with Diabetes
Topics: Adenocarcinoma, Clear Cell; Carcinoma, Papillary; Cystadenocarcinoma, Serous; Diabetes Mellitus, Typ | 2018 |
Statins are Associated With Increased Biochemical Recurrence After Radical Prostatectomy in Diabetic Men but no Association was Seen in Men also Taking Metformin: Results From the SEARCH Database.
Topics: Aged; Cohort Studies; Databases, Factual; Diabetes Mellitus; Drug Therapy, Combination; Follow-Up St | 2019 |
Metformin and tenovin-6 synergistically induces apoptosis through LKB1-independent SIRT1 down-regulation in non-small cell lung cancer cells.
Topics: Acetylation; Adenocarcinoma of Lung; AMP-Activated Protein Kinase Kinases; Antineoplastic Agents; Ap | 2019 |
Association between diabetes and oncological outcomes in patients undergoing neoadjuvant chemo-radiotherapy for rectal cancer.
Topics: Aged; Aged, 80 and over; Chemoradiotherapy, Adjuvant; Diabetes Mellitus; Female; Follow-Up Studies; | 2019 |
[Efficacy and safety of metformin for Behcet's disease and its effect on Treg/Th17 balance: a single-blinded, before-after study].
Topics: Behcet Syndrome; Controlled Before-After Studies; Forkhead Transcription Factors; Humans; Immunosupp | 2019 |
Effects of metformin and phenformin on apoptosis and epithelial-mesenchymal transition in chemoresistant rectal cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Movement; | 2019 |
Effect of metformin on prostate cancer outcomes after radical prostatectomy.
Topics: Aged; Follow-Up Studies; Humans; Hypoglycemic Agents; Kaplan-Meier Estimate; Male; Metformin; Middle | 2014 |
[Poor prognostic value of weight change during chemotherapy in non-metastatic breast cancer patients: causes, mechanisms involved and preventive strategies].
Topics: Adiposity; Antineoplastic Agents; Breast Neoplasms; Energy Metabolism; Exercise; Female; Humans; Hyp | 2013 |
Association of diabetes mellitus and metformin use with oncological outcomes of patients with non-muscle-invasive bladder cancer.
Topics: Aged; Aged, 80 and over; Diabetes Mellitus; Disease Progression; Disease-Free Survival; Female; Foll | 2013 |
Metformin does not affect risk of biochemical recurrence following radical prostatectomy: results from the SEARCH database.
Topics: Aged; Databases, Factual; Diabetes Mellitus; Follow-Up Studies; Humans; Hypoglycemic Agents; Male; M | 2013 |
Diabetes mellitus without metformin intake is associated with worse oncologic outcomes after radical nephroureterectomy for upper tract urothelial carcinoma.
Topics: Aged; Carcinoma, Transitional Cell; Diabetes Mellitus; Female; Follow-Up Studies; Humans; Hypoglycem | 2014 |
Metformin use and improved response to therapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Chemoradiotherapy, Adjuvant; Diabetes Mellitus, Type | 2013 |
Effect of diabetes mellitus and metformin use on oncologic outcomes of patients treated with radical cystectomy for urothelial carcinoma.
Topics: Aged; Carcinoma, Transitional Cell; Cause of Death; Cystectomy; Diabetes Mellitus; Female; Follow-Up | 2014 |
Diabetes mellitus and non-muscle-invasive bladder cancer: not just a coincidence?
Topics: Diabetes Mellitus; Female; Humans; Hypoglycemic Agents; Male; Metformin; Neoplasm Recurrence, Local; | 2013 |
Metformin: a potential therapeutic agent for recurrent colon cancer.
Topics: Animals; Cell Movement; Colonic Neoplasms; Female; Fluorouracil; HCT116 Cells; HT29 Cells; Humans; M | 2014 |
[Hyperglycaemia during treatment with everolimus].
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Everolimus; Female; Humans; Hyperglycemia; Hypoglycem | 2014 |
Coencapsulation of epirubicin and metformin in PEGylated liposomes inhibits the recurrence of murine sarcoma S180 existing CD133+ cancer stem-like cells.
Topics: AC133 Antigen; Animals; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Ce | 2014 |
Effect of metformin on progression of head and neck cancers, occurrence of second primary cancers, and cause-specific survival.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Diabetes Mellitus; Female; Head and Neck N | 2015 |
Associations between diabetes medication use and risk of second breast cancer events and mortality.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Breast Neoplasms; Cohort Studies; Diabetes Mellitus; Fem | 2015 |
Metformin use improves the survival of diabetic combined small-cell lung cancer patients.
Topics: Aged; Diabetes Mellitus; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Lung Neoplasms; Mal | 2015 |
Metformin effects on biochemical recurrence and metabolic signaling in the prostate.
Topics: Aged; Databases, Factual; Diabetes Mellitus; Disease-Free Survival; Humans; Hypoglycemic Agents; Ins | 2015 |
Metformin represses cancer cells via alternate pathways in N-cadherin expressing vs. N-cadherin deficient cells.
Topics: AMP-Activated Protein Kinases; Animals; Antigens, CD; Antineoplastic Agents; Apoptosis; Cadherins; C | 2015 |
Use of Metformin in Obese Women With Type I Endometrial Cancer Is Associated With a Reduced Incidence of Cancer Recurrence.
Topics: Adult; Aged; Aged, 80 and over; Arkansas; Endometrial Neoplasms; Female; Humans; Hypoglycemic Agents | 2016 |
Association of Metformin Use with Outcomes in Advanced Endometrial Cancer Treated with Chemotherapy.
Topics: Adenocarcinoma, Clear Cell; Aged; Carcinosarcoma; Cystadenocarcinoma, Serous; Endometrial Neoplasms; | 2016 |
Effects of Statin, Aspirin or Metformin Use on Recurrence-Free and Overall Survival in Patients with Biliary Tract Cancer.
Topics: Aged; Aspirin; Biliary Tract Neoplasms; Cardiovascular Agents; Comorbidity; Disease Progression; Dis | 2015 |
Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models.
Topics: Acetyltransferases; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2016 |
Metformin exposure is associated with improved progression-free survival in diabetic patients after resection for early-stage non-small cell lung cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Diabetes Mellitus; Diabetes Mellitus, Type 2; Disease-Free Sur | 2016 |
The prognostic role of metformin in patients with endometrial cancer: a retrospective study.
Topics: Aged; Diabetes Mellitus, Type 2; Endometrial Neoplasms; Female; Humans; Hypoglycemic Agents; Metform | 2016 |
Tumor features and survival after radical prostatectomy among antidiabetic drug users.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Mal | 2016 |
Impact of Glycemic Control and Metformin Use on the Recurrence and Progression of Non-Muscle Invasive Bladder Cancer in Patients with Diabetes Mellitus.
Topics: Aged; Diabetes Mellitus, Type 2; Disease-Free Survival; Female; Glycated Hemoglobin; Humans; Kaplan- | 2016 |
Sirolimus and metformin synergistically inhibit hepatocellular carcinoma cell proliferation and improve long-term survival in patients with HCC related to hepatitis B virus induced cirrhosis after liver transplantation.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Line | 2016 |
Cyclin G2 promotes cell cycle arrest in breast cancer cells responding to fulvestrant and metformin and correlates with patient survival.
Topics: Breast Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Nucleus; Cyclin G2; Cyclin-Dependen | 2016 |
Metformin confers risk reduction for developing hepatocellular carcinoma recurrence after liver resection.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Female; Hepatectomy; Humans; Hypo | 2017 |
Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer Treatment Group N0147 (Alliance).
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colonic Neoplasms; DNA Mismatch Repair; Fema | 2016 |
Metformin Prevents the Progression of Dysplastic Mucosa of the Head and Neck to Carcinoma in Nondiabetic Patients.
Topics: Aged; Carcinoma, Squamous Cell; Disease Progression; Female; Glottis; Head and Neck Neoplasms; Human | 2017 |
The effect of metformin on the recurrence of colorectal adenoma in diabetic patients with previous colorectal adenoma.
Topics: Adenoma; Colorectal Neoplasms; Diabetes Mellitus; Female; Humans; Male; Metformin; Neoplasm Recurren | 2017 |